fluorouracil has been researched along with Bile Duct Neoplasms in 214 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Bile Duct Neoplasms: Tumors or cancer of the BILE DUCTS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The combination of gemcitabine and capecitabine is a well-tolerated regimen with activity in patients with advanced gallbladder cancer and cholangiocarcinoma." | 9.15 | A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202. ( Ahmad, SA; Blanke, CD; El-Khoueiry, AB; Gold, PJ; Holcombe, RF; Iqbal, S; Lenz, HJ; Messino, MJ; Rankin, C, 2011) |
| "Gemcitabine based regimens have been widely used in patients with advanced cholangiocarcinoma (CC), but no standard therapy exists." | 9.15 | A Phase I-II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas. ( Jakobsen, A; Jensen, LH; Lassen, U; Rohrberg, KS; Sorensen, M; Ujmajuridze, Z, 2011) |
| "Radiochemotherapy using gemcitabine followed by gemcitabine and capecitabine is an active regimen with manageable toxicity after resection of extrahepatic bile duct cancer but has significant toxicity in unresectable disease." | 9.12 | Radiochemotherapy followed by gemcitabine and capecitabine in extrahepatic bile duct cancer: a phase I/II trial. ( Caca, K; Hauss, J; Hildebrandt, G; Liebmann, A; Miethe, S; Mossner, J; Schoppmeyer, K; Wiedmann, M; Witzigmann, H, 2006) |
| "A patient receiving the antitumor agent mitomycin C (MMC) in combination with 5-fluorouracil and adriamycin because of adenocarcinoma of Vater's papilla manifested hemolytic-uremic syndrome (HUS) after five cycles of 5-fluorouracil-adriamycin-MMC combination chemotherapy." | 8.77 | Carcinoma-associated hemolytic-uremic syndrome in a patient receiving 5-fluorouracil-adriamycin-mitomycin C combination chemotherapy. ( Binsack, T; Mergenthaler, HG; Wilmanns, W, 1988) |
| "5-Fluorouracil (5-FU), a thymidylate synthase (TS) inhibitor, has been used as the first-line chemotherapeutic drug for cholangiocarcinoma (CCA)." | 8.02 | FOXM1 inhibitor, Siomycin A, synergizes and restores 5-FU cytotoxicity in human cholangiocarcinoma cell lines via targeting thymidylate synthase. ( Klinhom-On, N; Mahalapbutr, P; Obchoei, S; Sawanyawisuth, K; Seubwai, W; Wongkham, S, 2021) |
| "Application of 5-fluorouracil (5-FU) in cholangiocarcinoma (CCA) is limited by adverse side effects and chemoresistance." | 8.02 | Anticancer effects of the combined Thai noni juice ethanolic extracts and 5-fluorouracil against cholangiocarcinoma cells in vitro and in vivo. ( Jeeunngoi, J; Ketterman, AJ; Prompipak, J; Senawong, G; Senawong, T; Sripa, B; Utaiwat, S; Woranam, K, 2021) |
| "Fluorouracil (5-FU) is the first-line chemotherapeutic drug for cholangiocarcinoma (CCA), but its efficacy has been compromised by the development of resistance." | 7.88 | FOXM1 modulates 5-fluorouracil sensitivity in cholangiocarcinoma through thymidylate synthase (TYMS): implications of FOXM1-TYMS axis uncoupling in 5-FU resistance. ( Intuyod, K; Jiramongkol, Y; Lai, CF; Lam, EW; Luvira, V; Pairojkul, C; Pinlaor, S; Saavedra-García, P; Trakansuebkul, S; Vaeteewoottacharn, K; Waraasawapati, S; Wongkham, S; Yao, S; Yong, JS; Zona, S, 2018) |
| "To establish and characterize the gemcitabine-resistant cholangiocarcinoma (CCA) cell lines, CCA KKU‑M139 and KKU‑M214 cell lines were exposed stepwisely to increasing gemcitabine (GEM)." | 7.81 | Establishment and characterization of gemcitabine-resistant human cholangiocarcinoma cell lines with multidrug resistance and enhanced invasiveness. ( Boonmars, T; Hahnvajanawong, C; Jearanaikoon, P; Kanchanawat, S; Leelayuwat, C; Namwat, N; Seubwai, W; Techasen, A; Wattanawongdon, W, 2015) |
| "The aim of the present study was to investigate the role of NK4, an antagonist for hepatocyte growth factor (HGF) and the Met receptor, in regulating the response of cholangiocarcinoma (CCA) cells to 5-fluorouracil (5-FU)." | 7.79 | NK4 regulates 5-fluorouracil sensitivity in cholangiocarcinoma cells by modulating the intrinsic apoptosis pathway. ( Ge, X; Ji, G; Li, Q; Miao, L; Wang, Y; Yu, H, 2013) |
| "To determine whether expression of certain enzymes related to 5-fluorouracil (5-FU) metabolism predicts 5-FU chemosensitivity in cholangiocarcinoma (CCA)." | 7.78 | Orotate phosphoribosyl transferase mRNA expression and the response of cholangiocarcinoma to 5-fluorouracil. ( Bhudhisawasdi, V; Chaiyagool, J; Hahnvajanawong, C; Khuntikeo, N; Namwat, N; Pugkhem, A; Seubwai, W; Sripa, B; Tassaneeyakul, W, 2012) |
| "Inhibition of TP may be beneficial in decreasing angiogenesis-dependent growth and migration of cholangiocarcinoma but may diminish the response to 5-fluorouracil chemotherapy." | 7.76 | Effects of thymidine phosphorylase on tumor aggressiveness and 5-fluorouracil sensitivity in cholangiocarcinoma. ( Jearanaikoon, P; Limpaiboon, T; Miwa, M; Pairojkul, C; Sripa, B; Tantimavanich, S; Thanasai, J, 2010) |
| "We assessed the effect of purified green tea catechins on chemotherapy-induced apoptosis in KMCH, CC-LP-1 and Mz-ChA-1 human cholangiocarcinoma cells, and on chemosensitivity of Mz-ChA-1 cell xenografts in nude mice." | 7.75 | Epigallocatechin-gallate modulates chemotherapy-induced apoptosis in human cholangiocarcinoma cells. ( Braconi, C; Henson, R; Lang, M; Patel, T, 2009) |
| "The authors performed a retrospective analysis of all patients with hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), or gallbladder carcinoma (GBC) who were ever treated with oral capecitabine." | 7.72 | Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. ( Aguayo, A; Brown, TD; Charnsangavej, C; Curley, SA; Ellis, LM; Hassan, MM; Lozano, RD; Nooka, AK; Patt, YZ; Schnirer, II; Vauthey, JN; Wolff, RA, 2004) |
| "Capecitabine could potentially be used for secondline treatment in patients with progressive metastatic cholangiocarcinoma." | 7.71 | Capecitabine as second-line treatment for metastatic cholangiocarcinoma: a report of two cases. ( Heinemann, V; Schalhorn, A; Stemmler, J, 2002) |
| "A 64-year-old woman who was diagnosed as inoperable intrahepatic bile duct cancer with massive liver metastasis was treated with 5-fluorouracil (5-FU), adriamycin (ADM) and mitomycin-C (MMC)." | 7.67 | [A case of intrahepatic bile duct cancer responding to 5-fluorouracil, adriamycin and mitomycin C chemotherapy]. ( Hasegawa, H; Kozakai, M; Misu, Y; Saitoh, Y; Shikata, J; Takada, T; Tsuchiya, S; Uchiyama, K; Yasuda, H, 1988) |
| "The adjuvant therapy (AT) for biliary tract cancer (BTC) patients after surgery has always been controversial." | 6.82 | The efficacy and safety of 5-fluorouracil based adjuvant therapy in resected biliary tract cancer: A systematic review and meta-analysis. ( Cheng, Q; Gong, S; Guo, T; Lei, C; Lu, T; Lv, K; Song, S; Tian, H; Yang, K; Yang, W, 2022) |
| "The role of postoperative therapy in extrahepatic cholangiocarcinoma (EHCC) or gallbladder carcinoma (GBCA) is unknown." | 6.80 | SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma. ( Alberts, SR; Ben-Josef, E; Blanke, CD; Corless, CL; Dawson, LA; El-Khoueiry, AB; Guthrie, KA; Lowy, AM; Micetich, KC; Siegel, AB; Thomas, CR; Thomas, MB; Zalupski, MM, 2015) |
| "Bile duct cancer is characterized by fast metastasis and invasion and has been regarded as one of the most aggressive tumors due to the absence of effective diagnosis at an early stage." | 5.51 | Raddeanin A promotes apoptosis and ameliorates 5-fluorouracil resistance in cholangiocarcinoma cells. ( Fan, QX; Guo, SS; Wang, Y, 2019) |
| "(Ham-1) cells both in vitro and in vivo." | 5.46 | Synergistic Effect of Forbesione From Garcinia hanburyi in Combination with 5-Fluorouracil on Cholangiocarcinoma ( Anantachoke, N; Boonmars, T; Boueroy, P; Hahnvajanawong, C; Kongsanthia, C; Reutrakul, V; Saensa-ard, S; Salao, K; Wattanawongdon, W; Wongwajana, S, 2017) |
| "Cholangiocarcinoma is categorized into intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC)." | 5.40 | Efficacy of hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic pegylated interferon α-2b for advanced intrahepatic cholangiocarcinoma. ( Kasai, K; Kasai, Y; Kooka, Y; Miyamoto, Y; Oikawa, K; Oikawa, T; Sawara, K; Suzuki, A; Suzuki, Y; Takikawa, Y; Ushio, A, 2014) |
| "Capecitabine was administered orally at a dose of 1,000 mg/m(2) twice a day for 14 days, followed by a 1-week rest period." | 5.38 | Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study. ( Han, SS; Hong, EK; Kim, CM; Kim, HB; Kim, TH; Koh, YH; Lee, WJ; Park, JW; Park, SJ; Woo, SM, 2012) |
| " The treatment did not cause any serious adverse events, except hypercalcemia grade I, once in 72 administrations." | 5.38 | Evaluation of efficacy, safety and tolerability of high dose-intermittent calcitriol supplementation to advanced intrahepatic cholangiocarcinoma patients--a pilot study. ( Bhudhisawasdi, V; Chamadol, N; Chur-in, S; Janeklang, S; Khuntikeo, N; Kukongviriyapan, V; Pairojkul, C; Prawan, A; Pugkhem, A; Sookprasert, A; Vaeteewoottacharn, K; Wongkham, S, 2012) |
| " We determined the anticancer effects of VPA combined with 5-FU in these cell lines." | 5.37 | Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell lines. ( Hanaoka, J; Ikemoto, T; Imura, S; Ishibashi, H; Iwahashi, S; Mori, H; Morine, Y; Ochir, TL; Shimada, M; Utsunomiya, T, 2011) |
| "The prognosis of bile duct cancer is still poor." | 5.27 | [Intraductal chemotherapy of bile duct cancer with 5-fluorouracil]. ( Arnold, W; Bartels, E; Schmeck, HJ; Viets, CH, 1986) |
| "The combination of gemcitabine and capecitabine is a well-tolerated regimen with activity in patients with advanced gallbladder cancer and cholangiocarcinoma." | 5.15 | A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202. ( Ahmad, SA; Blanke, CD; El-Khoueiry, AB; Gold, PJ; Holcombe, RF; Iqbal, S; Lenz, HJ; Messino, MJ; Rankin, C, 2011) |
| "Gemcitabine based regimens have been widely used in patients with advanced cholangiocarcinoma (CC), but no standard therapy exists." | 5.15 | A Phase I-II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas. ( Jakobsen, A; Jensen, LH; Lassen, U; Rohrberg, KS; Sorensen, M; Ujmajuridze, Z, 2011) |
| "Radiochemotherapy using gemcitabine followed by gemcitabine and capecitabine is an active regimen with manageable toxicity after resection of extrahepatic bile duct cancer but has significant toxicity in unresectable disease." | 5.12 | Radiochemotherapy followed by gemcitabine and capecitabine in extrahepatic bile duct cancer: a phase I/II trial. ( Caca, K; Hauss, J; Hildebrandt, G; Liebmann, A; Miethe, S; Mossner, J; Schoppmeyer, K; Wiedmann, M; Witzigmann, H, 2006) |
| "A patient receiving the antitumor agent mitomycin C (MMC) in combination with 5-fluorouracil and adriamycin because of adenocarcinoma of Vater's papilla manifested hemolytic-uremic syndrome (HUS) after five cycles of 5-fluorouracil-adriamycin-MMC combination chemotherapy." | 4.77 | Carcinoma-associated hemolytic-uremic syndrome in a patient receiving 5-fluorouracil-adriamycin-mitomycin C combination chemotherapy. ( Binsack, T; Mergenthaler, HG; Wilmanns, W, 1988) |
| " We aim to explore the roles of LncFALEC and miR-20a-5p/SHOC2 axis on the proliferation, migration, and Fluorouracil (5-FU) resistance of cholangiocarcinoma (CCA)." | 4.31 | LncRNA FALEC increases the proliferation, migration and drug resistance of cholangiocarcinoma through competitive regulation of miR-20a-5p/SHOC2 axis. ( Du, H; Hou, S; Liu, C; Yu, T; Zhang, L; Zhang, W, 2023) |
| "5-Fluorouracil (5-FU), a thymidylate synthase (TS) inhibitor, has been used as the first-line chemotherapeutic drug for cholangiocarcinoma (CCA)." | 4.02 | FOXM1 inhibitor, Siomycin A, synergizes and restores 5-FU cytotoxicity in human cholangiocarcinoma cell lines via targeting thymidylate synthase. ( Klinhom-On, N; Mahalapbutr, P; Obchoei, S; Sawanyawisuth, K; Seubwai, W; Wongkham, S, 2021) |
| "Application of 5-fluorouracil (5-FU) in cholangiocarcinoma (CCA) is limited by adverse side effects and chemoresistance." | 4.02 | Anticancer effects of the combined Thai noni juice ethanolic extracts and 5-fluorouracil against cholangiocarcinoma cells in vitro and in vivo. ( Jeeunngoi, J; Ketterman, AJ; Prompipak, J; Senawong, G; Senawong, T; Sripa, B; Utaiwat, S; Woranam, K, 2021) |
| "Fluorouracil (5-FU) is the first-line chemotherapeutic drug for cholangiocarcinoma (CCA), but its efficacy has been compromised by the development of resistance." | 3.88 | FOXM1 modulates 5-fluorouracil sensitivity in cholangiocarcinoma through thymidylate synthase (TYMS): implications of FOXM1-TYMS axis uncoupling in 5-FU resistance. ( Intuyod, K; Jiramongkol, Y; Lai, CF; Lam, EW; Luvira, V; Pairojkul, C; Pinlaor, S; Saavedra-García, P; Trakansuebkul, S; Vaeteewoottacharn, K; Waraasawapati, S; Wongkham, S; Yao, S; Yong, JS; Zona, S, 2018) |
| "We aimed to present the clinical outcomes of adjuvant concurrent chemoradiotherapy (CCRT) with low-dose daily cisplatin regimen compared to the conventional 5-fluorouracil (5-FU)-based regimen for extrahepatic bile duct cancer (EHBDC)." | 3.85 | Adjuvant concurrent chemoradiotherapy with low-dose daily cisplatin for extrahepatic bile duct cancer. ( Chun, M; Kang, SY; Kim, JH; Kim, SW; Lee, HW; Noh, OK; Oh, YT; Park, RW; Yoon, D, 2017) |
| "Thirteen consecutive patients with metastatic intrahepatic cholangiocarcinoma who were refractory to first-line therapy consisting of gemcitabine plus oxaliplatin-based first-line chemotherapy given intravenously via intra-arterial infusion were treated with FOLFIRI [irinotecan (180 mg/m² i." | 3.81 | FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma. ( Bengrine, L; Ghiringhelli, F; Guion-Dusserre, JF; Lorgis, V; Vincent, J, 2015) |
| "To establish and characterize the gemcitabine-resistant cholangiocarcinoma (CCA) cell lines, CCA KKU‑M139 and KKU‑M214 cell lines were exposed stepwisely to increasing gemcitabine (GEM)." | 3.81 | Establishment and characterization of gemcitabine-resistant human cholangiocarcinoma cell lines with multidrug resistance and enhanced invasiveness. ( Boonmars, T; Hahnvajanawong, C; Jearanaikoon, P; Kanchanawat, S; Leelayuwat, C; Namwat, N; Seubwai, W; Techasen, A; Wattanawongdon, W, 2015) |
| "To determine whether magnetic resonance (MR) imaging heating guidewire-mediated radiofrequency (RF) hyperthermia could enhance the therapeutic effect of gemcitabine and 5-fluorouracil (5-FU) in a cholangiocarcinoma cell line and local deposit doses of chemotherapeutic drugs in swine common bile duct (CBD) walls." | 3.80 | Intrabiliary RF heat-enhanced local chemotherapy of a cholangiocarcinoma cell line: monitoring with dual-modality imaging--preclinical study. ( Kolokythas, O; Le, T; Meng, Y; Soriano, SS; Wang, H; Wei, B; Willis, P; Wu, X; Yang, X; Zhang, F; Zhang, T, 2014) |
| "The aim of the present study was to investigate the role of NK4, an antagonist for hepatocyte growth factor (HGF) and the Met receptor, in regulating the response of cholangiocarcinoma (CCA) cells to 5-fluorouracil (5-FU)." | 3.79 | NK4 regulates 5-fluorouracil sensitivity in cholangiocarcinoma cells by modulating the intrinsic apoptosis pathway. ( Ge, X; Ji, G; Li, Q; Miao, L; Wang, Y; Yu, H, 2013) |
| "Tumor control and survival of patient with advanced cholangiocarcinoma treated with gemcitabine-based and 5FU-based chemotherapy do not markedly differ." | 3.79 | Treatment outcome of palliative chemotherapy in inoperable cholangiocarcinoma in Thailand. ( Butthongkomvong, K; Jhankumpha, S; Kumdang, S; Sirachainan, E; Sukhontharot, OU, 2013) |
| "To determine whether expression of certain enzymes related to 5-fluorouracil (5-FU) metabolism predicts 5-FU chemosensitivity in cholangiocarcinoma (CCA)." | 3.78 | Orotate phosphoribosyl transferase mRNA expression and the response of cholangiocarcinoma to 5-fluorouracil. ( Bhudhisawasdi, V; Chaiyagool, J; Hahnvajanawong, C; Khuntikeo, N; Namwat, N; Pugkhem, A; Seubwai, W; Sripa, B; Tassaneeyakul, W, 2012) |
| "Inhibition of TP may be beneficial in decreasing angiogenesis-dependent growth and migration of cholangiocarcinoma but may diminish the response to 5-fluorouracil chemotherapy." | 3.76 | Effects of thymidine phosphorylase on tumor aggressiveness and 5-fluorouracil sensitivity in cholangiocarcinoma. ( Jearanaikoon, P; Limpaiboon, T; Miwa, M; Pairojkul, C; Sripa, B; Tantimavanich, S; Thanasai, J, 2010) |
| "We assessed the effect of purified green tea catechins on chemotherapy-induced apoptosis in KMCH, CC-LP-1 and Mz-ChA-1 human cholangiocarcinoma cells, and on chemosensitivity of Mz-ChA-1 cell xenografts in nude mice." | 3.75 | Epigallocatechin-gallate modulates chemotherapy-induced apoptosis in human cholangiocarcinoma cells. ( Braconi, C; Henson, R; Lang, M; Patel, T, 2009) |
| " We evaluated the effects of these adenoviruses with 5-fluorouracil (5-FU) and/or ganciclovir (GCV) on human cholangiocarcinoma cells (HuCCT1, with mutant p53) in vitro and in vivo." | 3.75 | Oncolytic gene therapy combined with double suicide genes for human bile duct cancer in nude mouse models. ( Hamada, H; Honda, K; Kobayashi, N; Kojima, Y, 2009) |
| "The authors performed a retrospective analysis of all patients with hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), or gallbladder carcinoma (GBC) who were ever treated with oral capecitabine." | 3.72 | Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. ( Aguayo, A; Brown, TD; Charnsangavej, C; Curley, SA; Ellis, LM; Hassan, MM; Lozano, RD; Nooka, AK; Patt, YZ; Schnirer, II; Vauthey, JN; Wolff, RA, 2004) |
| "Capecitabine could potentially be used for secondline treatment in patients with progressive metastatic cholangiocarcinoma." | 3.71 | Capecitabine as second-line treatment for metastatic cholangiocarcinoma: a report of two cases. ( Heinemann, V; Schalhorn, A; Stemmler, J, 2002) |
| "Four patients with gallbladder cancer and two with bile duct cancer were treated with mitomycin C, carboquone, 5-fluorouracil and OK-432 (MQF-OK therapy) plus tegafur (FT) or UFT." | 3.67 | [MQF-FT and MQF-UFT in gallbladder and bile duct cancer]. ( Fukushi, G; Itoh, T; Kimura, M; Kimura, T; Kishibe, T; Saitoh, S; Sakata, Y; Suzuki, H; Tamura, Y; Tsushima, K, 1988) |
| "A 64-year-old woman who was diagnosed as inoperable intrahepatic bile duct cancer with massive liver metastasis was treated with 5-fluorouracil (5-FU), adriamycin (ADM) and mitomycin-C (MMC)." | 3.67 | [A case of intrahepatic bile duct cancer responding to 5-fluorouracil, adriamycin and mitomycin C chemotherapy]. ( Hasegawa, H; Kozakai, M; Misu, Y; Saitoh, Y; Shikata, J; Takada, T; Tsuchiya, S; Uchiyama, K; Yasuda, H, 1988) |
| "Twelve patients with adenocarcinoma of the pancreas and two patients with carcinoma of the extrahepatic biliary tree received combined therapy with 125I implant, precision high-dose (PHD) photon external beam therapy, and systemic 5-fluorouracil (5-FU)." | 3.67 | 125I interstitial implant, precision high-dose external beam therapy, and 5-FU for unresectable adenocarcinoma of pancreas and extrahepatic biliary tree. ( Ahuja, RK; Dobelbower, RR; Merrick, HW; Skeel, RT, 1986) |
| "Cholangiocarcinoma is a deadly cancer comprising very heterogenous subtypes with a limited therapeutic arsenal in all comers." | 3.01 | Cholangiocarcinoma: what are the options in all comers and how has the advent of molecular profiling opened the way to personalised medicine ? ( Edeline, J; Lièvre, A; Malka, D; Neuzillet, C; Roth, GS; Sarabi, M, 2023) |
| "Patients with pancreatic cancer were given the digestive enzyme supplement LipaCreon® from the fifth week after the start of administration." | 2.87 | Effects of ω-3 Fatty Acid Supplementation in Patients with Bile Duct or Pancreatic Cancer Undergoing Chemotherapy. ( Abe, K; Gocho, T; Haruki, K; Onda, S; Sakamoto, T; Takano, Y; Uwagawa, T; Yanaga, K, 2018) |
| "The adjuvant therapy (AT) for biliary tract cancer (BTC) patients after surgery has always been controversial." | 2.82 | The efficacy and safety of 5-fluorouracil based adjuvant therapy in resected biliary tract cancer: A systematic review and meta-analysis. ( Cheng, Q; Gong, S; Guo, T; Lei, C; Lu, T; Lv, K; Song, S; Tian, H; Yang, K; Yang, W, 2022) |
| "The role of postoperative therapy in extrahepatic cholangiocarcinoma (EHCC) or gallbladder carcinoma (GBCA) is unknown." | 2.80 | SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma. ( Alberts, SR; Ben-Josef, E; Blanke, CD; Corless, CL; Dawson, LA; El-Khoueiry, AB; Guthrie, KA; Lowy, AM; Micetich, KC; Siegel, AB; Thomas, CR; Thomas, MB; Zalupski, MM, 2015) |
| " After two cycles, a 4-week outpatient treatment of gemcitabine (1000 mg/m(2)) on days 1 and 15 combined with 5-FU (500 mg/m(2)) and CDDP (7 mg/m(2)) on days 1 and 15 was commenced." | 2.75 | Phase II trial of gemcitabine combined with 5-fluorouracil and cisplatin (GFP) chemotherapy in patients with advanced biliary tree cancers. ( Gion, T; Harimoto, N; Itoh, S; Maehara, Y; Sugimachi, K; Taketomi, A; Tsujita, E; Yamashita, Y, 2010) |
| " Treatment consisted of capecitabine (2,000 mg/m(2) days 1-14) in combination with docetaxel (40 mg/m(2) day 1) and mitomycin C (4 mg/m(2) day 1)." | 2.75 | Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma. ( Ernst, T; Hochhaus, A; Hofheinz, RD; Hofmann, WK; Kripp, M; Kruth, J; Lukan, N; Merx, K; Nissen, J, 2010) |
| "Intrahepatic cholangiocellular carcinoma after curative surgery was treated with pharmacokinetic modulation chemotherapy (PMC) as adjuvant chemotherapy." | 2.74 | [Effects of pharmacokinetic modulation chemotherapy (PMC) using oral UFT and venous 5-FU infusion as adjuvant chemotherapy for intrahepatic cholangiocellular carcinoma]. ( Fukumori, D; Kamachi, H; Kamiyama, T; Matsushita, M; Nakagawa, T; Nakanishi, K; Tahara, M; Todo, S; Yokoo, H, 2009) |
| "Our results show that the regimen of gemcitabine combined with capecitabine is effective and well tolerated in patients with unresectable relapsed or metastatic carcinoma of the biliary tract." | 2.73 | [Gemcitabine combined with capecitabine in the treatment for 41 patients with relapsed or metastatic biliary tract carcinoma]. ( Chen, X; Chen, ZS; Li, J; Ouyang, XN; Xie, FW; Yu, ZY, 2008) |
| "Extrahepatic biliary tract and pancreatic cancer are relatively rare malignant tumors." | 2.73 | [Assessment of the value of PEF (cisplatin, epirubicin, 5 fluorouracil) in advanced extrahepatic biliary tract and pancreatic cancer]. ( Pawlega, J; Zygulska, AL, 2008) |
| "Three of 34 patients with bile duct cancer (1/12 [8%] on 5-FU, 0/10 on 5-FU + Stz, and 2/12 on 5-FU + MeCCNU) had objective response to treatment." | 2.65 | Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. ( Falkson, G; MacIntyre, JM; Moertel, CG, 1984) |
| "Most patients with intrahepatic cholangiocarcinoma (IH-CCA) are unresectable and treatment options are limited." | 2.52 | Intrahepatic chemotherapy for unresectable cholangiocarcinoma: review of literature and personal experience. ( Bassi, N; Bonariol, L; Bonariol, R; Caratozzolo, E; Massani, M; Morana, G; Nistri, C; Pauletti, B; Ruffolo, C, 2015) |
| "Gallbladder cancer is an aggressive tumor." | 2.46 | [Chemotherapy in gallbladder carcinoma]. ( Abahssain, H; Afchain, P; Errihani, H; Ismaili, N; Melas, N; Rabti, HM; Rahali, R, 2010) |
| "Cholangiocarcinoma is a rare malignancy arising from the bile duct epithelium with a grim prognosis." | 2.45 | Role of liver transplantation in the treatment of cholangiocarcinoma. ( Marrero, JA; Singal, A; Welling, TH, 2009) |
| " The purpose of this article is to review the available information on capecitabine with respect to clinical efficacy for tumors of the digestive tract, adverse-effect profile, documented drug interactions, dosage and administration, and future directions of ongoing research." | 2.45 | The role of capecitabine in the management of tumors of the digestive system. ( Gennatas, C; Gennatas, S; Michalaki, V, 2009) |
| "Capecitabine was the most common second-line chemotherapy treatment." | 1.91 | Use, response and outcomes of second-line chemotherapy in patients with advanced biliary tract cancers. ( Abadi, S; Davies, JM; Ho, C; Mathers, B; McIntyre, C, 2023) |
| "Our results provide preliminary evidence that HAIC based on FOLFIRI regimen is efficient and safe in some patients progressing after previous treatment." | 1.72 | The Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Based on FOLFIRI for Advanced Intrahepatic Cholangiocarcinoma as Second-Line and Successive Treatment: A Real-World Study. ( Chen, Y; Huang, P; Huang, X; Shi, G; Sun, Q; Yang, G; Zhou, Y, 2022) |
| "Cholangiocarcinoma is the first most common cancer of the biliary tract." | 1.62 | In Vitro Evaluation of Rigosertib Antitumoral and Radiosensitizing Effects against Human Cholangiocarcinoma Cells. ( Cavaletti, G; Celio, L; Damian, S; Malacrida, A; Mazzaferro, V; Miloso, M; Rigolio, R, 2021) |
| "Bile duct cancer is characterized by fast metastasis and invasion and has been regarded as one of the most aggressive tumors due to the absence of effective diagnosis at an early stage." | 1.51 | Raddeanin A promotes apoptosis and ameliorates 5-fluorouracil resistance in cholangiocarcinoma cells. ( Fan, QX; Guo, SS; Wang, Y, 2019) |
| "Management of advanced intrahepatic cholangiocarcinoma (iCCA) is challenging and overall survival is poor." | 1.51 | Prolonged Response to Anti-PD-1 Antibody Therapy in Chemotherapy-Refractory Cholangiocarcinoma With High Tumor Mutational Burden. ( Gbolahan, O; Hashemi-Sadraei, N; O'Neil, B, 2019) |
| "(Ham-1) cells both in vitro and in vivo." | 1.46 | Synergistic Effect of Forbesione From Garcinia hanburyi in Combination with 5-Fluorouracil on Cholangiocarcinoma ( Anantachoke, N; Boonmars, T; Boueroy, P; Hahnvajanawong, C; Kongsanthia, C; Reutrakul, V; Saensa-ard, S; Salao, K; Wattanawongdon, W; Wongwajana, S, 2017) |
| "The aim of this retrospective study was to clarify the effectiveness of chemotherapy with gemcitabine combined with low-dose 5-fluorouracil and cisplatin (GFP) for advanced biliary carcinoma after hepatectomy." | 1.46 | Effect of Adjuvant Gemcitabine Combined with Low-dose 5-Fluorouracil and Cisplatin Chemotherapy for Advanced Biliary Carcinoma. ( Arakawa, Y; Ikemoto, T; Imura, S; Iwahashi, S; Morine, Y; Saito, YU; Shimada, M; Yamada, S, 2017) |
| "We investigated the sensitivity of intrahepatic cholangiocarcinoma (IHCCA) subtypes to chemotherapeutics and molecular targeted agents." | 1.42 | Sensitivity of Human Intrahepatic Cholangiocarcinoma Subtypes to Chemotherapeutics and Molecular Targeted Agents: A Study on Primary Cell Cultures. ( Alvaro, D; Bragazzi, MC; Cardinale, V; Carpino, G; Costantini, D; De Rose, AM; Di Matteo, S; Fraveto, A; Gaudio, E; Giuliante, F; Grazi, GL; Lustri, AM; Napoletano, C; Nevi, L; Renzi, A; Semeraro, R, 2015) |
| " In this study, we aimed to investigate the therapeutic effect of TRAIL in CCA cell lines (M213, M214 and KKU100) compared with the immortal biliary cell line, MMNK1, either alone or in combination with a subtoxic dose of 5-fluorouracil (5-FU)." | 1.42 | TRAIL in Combination with Subtoxic 5-FU Effectively Inhibit Cell Proliferation and Induce Apoptosis in Cholangiocarcinoma Cells. ( Limpaiboon, T; Sriraksa, R, 2015) |
| "Combination therapy with 5-FU and interferon-α was safe and may improve the prognosis of advanced biliary carcinomas." | 1.42 | Intraarterial 5-fluorouracil and interferon therapy is safe and effective for nonresectable biliary tract adenocarcinoma. ( Kanda, M; Kawai, T; Obi, S; Sato, S; Sato, T; Sugimoto, T; Yashima, Y, 2015) |
| "Cholangiocarcinoma is categorized into intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC)." | 1.40 | Efficacy of hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic pegylated interferon α-2b for advanced intrahepatic cholangiocarcinoma. ( Kasai, K; Kasai, Y; Kooka, Y; Miyamoto, Y; Oikawa, K; Oikawa, T; Sawara, K; Suzuki, A; Suzuki, Y; Takikawa, Y; Ushio, A, 2014) |
| "Chemoimmunotherapy has been used to treat intrahepatic cholangiocarcinoma (ICC)." | 1.40 | Immunogenic modulation of cholangiocarcinoma cells by chemoimmunotherapy. ( Gong, J; Homma, S; Ito, M; Kajihara, M; Kan, S; Koido, S; Namiki, Y; Odahara, S; Ohkusa, T; Okamoto, M; Sugiyama, H; Tajiri, H; Takakura, K; Tsukinaga, S; Yoshida, K; Yoshizaki, S; Yusa, S, 2014) |
| "Patients were eligible if they had intrahepatic cholangiocarcinoma with liver or extrahepatic metastasis and with no prior chemotherapy." | 1.39 | Retrospective analysis of survival benefits of chemotherapy for metastatic or non-resectable intrahepatic cholangiocarcinoma. ( Chauffert, B; Ghiringhelli, F; Wiazzane, N, 2013) |
| "Intrahepatic and extrahepatic cholangiocarcinoma were observed in 57 and 21 patients, respectively." | 1.38 | Chemotherapy for inoperable advanced or metastatic cholangiocarcinoma: retrospective analysis of 78 cases in a single center over four years. ( Audrain, O; Boucher, E; Boudjema, K; Le Roux, G; Manfredi, S; Mesbah, H; Pracht, M; Raoul, JL; Sulpice, L, 2012) |
| "Capecitabine was administered orally at a dose of 1,000 mg/m(2) twice a day for 14 days, followed by a 1-week rest period." | 1.38 | Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study. ( Han, SS; Hong, EK; Kim, CM; Kim, HB; Kim, TH; Koh, YH; Lee, WJ; Park, JW; Park, SJ; Woo, SM, 2012) |
| "We report a case of acute inflammatory demyelinating polyradiculoneuropathy (AIDP) that developed in a patient with cholangiocarcinoma after receiving oxaliplatin-based chemotherapy." | 1.38 | Acute inflammatory demyelinating polyradiculoneuropathy in a patient receiving oxaliplatin-based chemotherapy. ( Bae, WK; Cho, SH; Chung, IJ; Hwang, JE; Kim, MK; Nam, TS; Shim, HJ; Yoon, JY, 2012) |
| " The treatment did not cause any serious adverse events, except hypercalcemia grade I, once in 72 administrations." | 1.38 | Evaluation of efficacy, safety and tolerability of high dose-intermittent calcitriol supplementation to advanced intrahepatic cholangiocarcinoma patients--a pilot study. ( Bhudhisawasdi, V; Chamadol, N; Chur-in, S; Janeklang, S; Khuntikeo, N; Kukongviriyapan, V; Pairojkul, C; Prawan, A; Pugkhem, A; Sookprasert, A; Vaeteewoottacharn, K; Wongkham, S, 2012) |
| " Novel neoadjuvant therapy protocols combined with demolitive surgery and liver transplantation seem to achieve successful results in terms of overall and disease-free survivals." | 1.37 | Neoadjuvant therapy protocol and liver transplantation in combination with pancreatoduodenectomy for the treatment of hilar cholangiocarcinoma occurring in a case of primary sclerosing cholangitis: case report with a more than 8-year disease-free survival ( Bassi, D; Boccagni, P; Boetto, R; Cillo, U; D'Amico, F; D'Amico, FE; Gringeri, E; Lodo, E; Polacco, M; Vitale, A; Zanus, G, 2011) |
| " We determined the anticancer effects of VPA combined with 5-FU in these cell lines." | 1.37 | Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell lines. ( Hanaoka, J; Ikemoto, T; Imura, S; Ishibashi, H; Iwahashi, S; Mori, H; Morine, Y; Ochir, TL; Shimada, M; Utsunomiya, T, 2011) |
| "Extrahepatic cholangiocarcinoma is a rare malignancy." | 1.35 | Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. ( Bendell, JC; Clary, BM; Clough, RW; Czito, BG; Ghafoori, AP; Hurwitz, HI; Morse, MA; Nelson, JW; Pappas, TN; Tyler, DS; Willett, CG, 2009) |
| "Twenty-nine patients with pancreatic cancer (PC) and 43 with biliary tract cancer (BTC; 27 cases of bile duct cancer, 8 of gallbladder cancer and 8 of cancer of the papillary area) were included." | 1.35 | Thymidylate synthase and dihydropyrimidine dehydrogenase are upregulated in pancreatic and biliary tract cancers. ( Kubota, K; Sawada, T; Shimoda, M, 2009) |
| "A 66-year-old man was diagnosed with hepatocellular carcinoma with Vp3 by abdominal enhanced CT." | 1.35 | [A case of successful multimodal treatment for combined hepatocellular and cholangiocarcinoma with portal venous tumor thrombus]. ( Doki, Y; Eguchi, H; Hatano, H; Kobayashi, S; Marubashi, S; Mori, M; Murakami, M; Nagano, H; Takeda, Y; Tanemura, M; Tomimaru, Y; Tomokuni, A; Wakasa, K, 2009) |
| "Cholangiocarcinoma is a malignant neoplasm arising from the biliary epithelium." | 1.34 | Effects of the anti-epidermal growth factor receptor antibody cetuximab on cholangiocarcinoma of the liver. ( Hsieh, CB; Huang, TW; Wang, CH, 2007) |
| "The high and medium dosage groups were significantly different from the control group (P<0." | 1.34 | Effects of targeting magnetic drug nanoparticles on human cholangiocarcinoma xenografts in nude mice. ( Ai, X; Chen, B; Li, H; Li, X; Tang, T; Xue, KY; Zheng, JW; Zou, SQ, 2007) |
| "She was first diagnosed as intrahepatic cholangiocarcinoma with hepatic, paraaortic lymphnodal and bone metastasis." | 1.33 | [A case of intrahepatic cholangiocarcinoma effectively treated by hepatic arterial infusion chemotherapy]. ( Hibi, T; Higuchi, H; Hisamatsu, T; Iizuka, H; Iwasaki, E; Izumiya, M; Masaoka, T; Nagata, H; Nishizawa, T; Suzuki, H; Takaishi, H; Yamagishi, Y, 2006) |
| "Nine of these 18 patients had bile duct cancer, seven had gallbladder cancer, and two had cancer of the papilla of Vater." | 1.32 | [Adjuvant arterial infusion chemotherapy for patients with biliary cancer]. ( Hasuike, Y; Kashiwazaki, M; Takeda, Y; Tsujinaka, T, 2004) |
| " The current study was performed to evaluate the outcome of patients with advanced hepatic hilar duct carcinoma who received external beam radiotherapy (EBRT) combined with transarterial chemotherapy and infusion of a vasoconstrictor." | 1.32 | Radiotherapy combined with transarterial infusion chemotherapy and concurrent infusion of a vasoconstrictor agent for nonresectable advanced hepatic hilar duct carcinoma. ( Hori, Y; Kiyosue, H; Komatsu, E; Matsumoto, A; Matsumoto, S; Mori, H; Tomonari, K; Wakisaka, M, 2004) |
| "Results of liver transplantation in the treatment of cholangiocarcinoma have been poor as a result of the high incidence of locoregional dissemination and tumor recurrence." | 1.31 | Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. ( Chinnakotla, S; DeRoover, A; Fox, I; Langnas, A; McCashland, T; Shaw, B; Sorrell, M; Sudan, D; Tempero, M, 2002) |
| "The first site of disease progression was local in 72% of cases." | 1.31 | Limitations of conventional doses of chemoradiation for unresectable biliary cancer. ( Brown, T; Charnsangavej, C; Crane, CH; Curley, S; Delclos, M; Janjan, NA; Macdonald, KO; Vauthey, JN; Wong, A; Yehuda, P, 2002) |
| "Lymph node metastasis was not present." | 1.31 | [Lymph node and peritoneum metastases of bile duct cancer responding to chronochemotherapy--a case report]. ( Iesato, H; Morishita, Y; Nakagami, K; Ohwada, S; Ohya, T; Sasaki, T; Sugitani, K; Takahashi, T; Yokomori, T, 2000) |
| " Radiation dose-response analysis, via clonogenic assay, was used as a more sensitive assay to confirm the interaction of the treatment conditions." | 1.30 | Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo. ( Buchsbaum, DJ; Curiel, DT; Kancharla, SR; Mayo, MS; Pederson, LC; Stackhouse, MA; Vickers, SM, 1997) |
| "Cholangiocarcinoma is the second most common primary tumor of the liver after hepatocellular carcinoma and accounts for 5 to 25% of primary hepatic malignancies." | 1.30 | Long-term survival of a young woman with peripheral cholangiocarcinoma: a case report. ( Chabot, J; Ishak, KG; Lefkowitch, J; Marvin, MR, 1999) |
| "A patient with advanced intrahepatic cholangiocarcinoma had a tumor embolus in the right main branch of the portal vein and lymph node metastases." | 1.30 | [A case report: successful resection of advanced intrahepatic cholangiocarcinoma responding to preoperative hepatic artery infusion of 5-FU]. ( Fujita, J; Hasuike, Y; Hattori, T; Hosoki, T; Kikkawa, N; Mishima, H; Mitomo, M; Motoori, M; Nishishou, I; Sai, H; Sawamura, T, 1999) |
| " Thus, both intraarterial and intraportal chemotherapy combined with decollateralization by silicone rubber sheeting seems to be effective for advanced cholangiocarcinoma and metastatic carcinoma." | 1.28 | [Intraarterial and intraportal chemotherapy combined with decollateralization for cholangiocellular carcinoma and metastatic liver cancer]. ( Fukuda, I; Furukawa, H; Imaoka, S; Ishikawa, O; Masutani, S; Nagano, H; Ohashi, I; Oohigashi, H; Sasaki, Y; Yasuda, T, 1990) |
| "The prognosis of bile duct cancer is still poor." | 1.27 | [Intraductal chemotherapy of bile duct cancer with 5-fluorouracil]. ( Arnold, W; Bartels, E; Schmeck, HJ; Viets, CH, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 32 (14.95) | 18.7374 |
| 1990's | 17 (7.94) | 18.2507 |
| 2000's | 53 (24.77) | 29.6817 |
| 2010's | 88 (41.12) | 24.3611 |
| 2020's | 24 (11.21) | 2.80 |
| Authors | Studies |
|---|---|
| Sribuhom, T | 1 |
| Boueroy, P | 2 |
| Hahnvajanawong, C | 5 |
| Phatchana, R | 1 |
| Yenjai, C | 1 |
| Klinhom-On, N | 1 |
| Seubwai, W | 4 |
| Sawanyawisuth, K | 2 |
| Obchoei, S | 1 |
| Mahalapbutr, P | 1 |
| Wongkham, S | 5 |
| Martviset, P | 1 |
| Panrit, L | 1 |
| Chantree, P | 1 |
| Muhamad, P | 1 |
| Na-Bangchang, K | 3 |
| Ishii, M | 1 |
| Itano, O | 1 |
| Morinaga, J | 1 |
| Shirakawa, H | 1 |
| Itano, S | 1 |
| Chen, M | 1 |
| Li, Y | 1 |
| Ma, N | 1 |
| Zang, J | 1 |
| Sonsomnuek, P | 1 |
| Tarasuk, M | 1 |
| Plengsuriyakarn, T | 1 |
| Boonprasert, K | 1 |
| Huang, P | 1 |
| Huang, X | 1 |
| Zhou, Y | 1 |
| Yang, G | 1 |
| Sun, Q | 1 |
| Shi, G | 1 |
| Chen, Y | 2 |
| Cosgrove, DP | 1 |
| Reese, ES | 1 |
| Fulcher, NM | 1 |
| Bobiak, SS | 1 |
| Lamy, FX | 1 |
| Allignol, A | 1 |
| Boyd, M | 1 |
| Mahmoudpour, SH | 1 |
| Mathers, B | 1 |
| Abadi, S | 1 |
| Davies, JM | 1 |
| McIntyre, C | 1 |
| Ho, C | 1 |
| Roth, GS | 3 |
| Neuzillet, C | 5 |
| Sarabi, M | 3 |
| Edeline, J | 4 |
| Malka, D | 4 |
| Lièvre, A | 4 |
| Yamagata, M | 1 |
| Nakajima, T | 2 |
| Aihara, T | 1 |
| Nishijima, N | 1 |
| Tomoo, Y | 1 |
| Matsuki, G | 1 |
| Fujikawa, M | 1 |
| Ichise, N | 1 |
| Kasai, M | 1 |
| Okamoto, R | 1 |
| Ikuta, S | 1 |
| Nakamoto, Y | 1 |
| Osaki, Y | 1 |
| Yanagi, H | 1 |
| Yamanaka, N | 2 |
| Hyung, J | 1 |
| Kim, I | 1 |
| Kim, KP | 1 |
| Ryoo, BY | 1 |
| Jeong, JH | 1 |
| Kang, MJ | 1 |
| Cheon, J | 1 |
| Kang, BW | 1 |
| Ryu, H | 1 |
| Lee, JS | 2 |
| Kim, KW | 1 |
| Abou-Alfa, GK | 1 |
| Yoo, C | 1 |
| Du, H | 1 |
| Hou, S | 1 |
| Zhang, L | 1 |
| Liu, C | 2 |
| Yu, T | 1 |
| Zhang, W | 2 |
| Wattanavises, S | 1 |
| Silsirivanit, A | 1 |
| Cha'on, U | 1 |
| Waraasawapati, S | 2 |
| Saentaweesuk, W | 1 |
| Luang, S | 1 |
| Chalermwat, C | 1 |
| Wongkham, C | 1 |
| Smart, AC | 1 |
| Goyal, L | 2 |
| Horick, N | 2 |
| Petkovska, N | 1 |
| Zhu, AX | 3 |
| Ferrone, CR | 2 |
| Tanabe, KK | 2 |
| Allen, JN | 2 |
| Drapek, LC | 2 |
| Qadan, M | 2 |
| Murphy, JE | 1 |
| Eyler, CE | 1 |
| Ryan, DP | 2 |
| Hong, TS | 2 |
| Wo, JY | 2 |
| Yang, J | 1 |
| Wang, J | 1 |
| Zhou, H | 1 |
| Wang, Y | 4 |
| Huang, H | 1 |
| Jin, H | 1 |
| Lou, Q | 1 |
| Shah, RJ | 1 |
| Zhang, X | 1 |
| Surinach, A | 1 |
| Phung, T | 1 |
| Abdul-Rahim, O | 1 |
| Khushman, M | 1 |
| Casadei-Gardini, A | 1 |
| Brieau, B | 1 |
| Vivaldi, C | 1 |
| Brandi, G | 2 |
| Tougeron, D | 1 |
| Filippi, R | 1 |
| Vienot, A | 1 |
| Silvestris, N | 1 |
| Pointet, AL | 1 |
| Lonardi, S | 1 |
| Rousseau, B | 1 |
| Scartozzi, M | 1 |
| Dahan, L | 1 |
| Aprile, G | 1 |
| Le Sourd, S | 1 |
| Evesque, L | 1 |
| Meurisse, A | 1 |
| Vernerey, D | 1 |
| Oguz, S | 1 |
| Kucukaslan, H | 1 |
| Topaloglu, S | 1 |
| Ones, T | 1 |
| Baltacioglu, F | 1 |
| Cobanoglu, U | 1 |
| Calik, A | 1 |
| Dee, EC | 1 |
| Freret, ME | 1 |
| Raldow, AC | 1 |
| Parikh, AR | 1 |
| Clark, JW | 1 |
| Fernandez-Del Castillo, C | 1 |
| Permpoon, U | 1 |
| Khan, F | 1 |
| Vadevoo, SMP | 1 |
| Gurung, S | 1 |
| Gunassekaran, GR | 1 |
| Kim, MJ | 1 |
| Kim, SH | 1 |
| Thuwajit, P | 1 |
| Lee, B | 1 |
| Gaddam, S | 1 |
| Coté, GA | 1 |
| Chen, L | 1 |
| Chen, W | 1 |
| Xu, S | 1 |
| Tang, L | 1 |
| Yang, Y | 1 |
| Li, Q | 2 |
| Jiang, Q | 1 |
| Miao, L | 2 |
| Prompipak, J | 1 |
| Senawong, T | 1 |
| Sripa, B | 4 |
| Ketterman, AJ | 1 |
| Utaiwat, S | 1 |
| Woranam, K | 1 |
| Jeeunngoi, J | 1 |
| Senawong, G | 1 |
| Malacrida, A | 1 |
| Rigolio, R | 1 |
| Celio, L | 1 |
| Damian, S | 1 |
| Cavaletti, G | 1 |
| Mazzaferro, V | 1 |
| Miloso, M | 1 |
| Song, S | 1 |
| Yang, W | 1 |
| Tian, H | 1 |
| Gong, S | 1 |
| Lei, C | 1 |
| Lv, K | 1 |
| Lu, T | 1 |
| Cheng, Q | 1 |
| Yang, K | 1 |
| Guo, T | 1 |
| Kim, SW | 5 |
| Noh, OK | 1 |
| Kim, JH | 3 |
| Chun, M | 1 |
| Oh, YT | 1 |
| Kang, SY | 1 |
| Lee, HW | 1 |
| Park, RW | 1 |
| Yoon, D | 1 |
| Schinzari, G | 1 |
| Rossi, E | 1 |
| Mambella, G | 1 |
| Strippoli, A | 1 |
| Cangiano, R | 1 |
| Mutignani, M | 2 |
| Basso, M | 1 |
| Cassano, A | 1 |
| Barone, C | 1 |
| Morine, Y | 2 |
| Shimada, M | 2 |
| Ikemoto, T | 2 |
| Arakawa, Y | 1 |
| Iwahashi, S | 2 |
| Saito, YU | 1 |
| Yamada, S | 1 |
| Imura, S | 2 |
| Bruckner, HW | 1 |
| Gurell, D | 1 |
| Hirschfeld, A | 1 |
| Boonmars, T | 2 |
| Saensa-ard, S | 1 |
| Wattanawongdon, W | 2 |
| Kongsanthia, C | 1 |
| Salao, K | 1 |
| Wongwajana, S | 1 |
| Anantachoke, N | 1 |
| Reutrakul, V | 1 |
| Park, Y | 1 |
| Kim, K | 4 |
| Paik, JH | 1 |
| Chie, EK | 4 |
| Jang, JY | 4 |
| Oh, DY | 4 |
| Abe, K | 1 |
| Uwagawa, T | 1 |
| Haruki, K | 1 |
| Takano, Y | 1 |
| Onda, S | 1 |
| Sakamoto, T | 1 |
| Gocho, T | 1 |
| Yanaga, K | 1 |
| Kobayashi, S | 3 |
| Terashima, T | 1 |
| Shiba, S | 1 |
| Yoshida, Y | 1 |
| Yamada, I | 1 |
| Iwadou, S | 1 |
| Horiguchi, S | 1 |
| Takahashi, H | 1 |
| Suzuki, E | 1 |
| Moriguchi, M | 1 |
| Tsuji, K | 1 |
| Otsuka, T | 1 |
| Asagi, A | 1 |
| Kojima, Y | 2 |
| Takada, R | 1 |
| Morizane, C | 1 |
| Mizuno, N | 1 |
| Ikeda, M | 1 |
| Ueno, M | 1 |
| Furuse, J | 1 |
| Srijiwangsa, P | 1 |
| Ponnikorn, S | 1 |
| Intuyod, K | 1 |
| Saavedra-García, P | 1 |
| Zona, S | 1 |
| Lai, CF | 1 |
| Jiramongkol, Y | 1 |
| Vaeteewoottacharn, K | 3 |
| Pairojkul, C | 3 |
| Yao, S | 1 |
| Yong, JS | 1 |
| Trakansuebkul, S | 1 |
| Luvira, V | 1 |
| Pinlaor, S | 1 |
| Lam, EW | 1 |
| Phelip, JM | 1 |
| Blanc, JF | 1 |
| Barbier, E | 1 |
| Michel, P | 1 |
| Bourgeois, V | 1 |
| Manfredi, S | 2 |
| Desrame, J | 1 |
| Miyata, T | 1 |
| Beppu, T | 2 |
| Imamura, YU | 1 |
| Hayashi, H | 3 |
| Imai, K | 1 |
| Chikamoto, A | 1 |
| Yamashita, YI | 1 |
| Fukubayashi, K | 1 |
| Ishiko, T | 2 |
| Baba, H | 2 |
| Qiu, G | 1 |
| Ma, D | 1 |
| Li, F | 1 |
| Sun, D | 1 |
| Zeng, Z | 1 |
| Bisello, S | 1 |
| Buwenge, M | 1 |
| Palloni, A | 1 |
| Autorino, R | 1 |
| Cellini, F | 1 |
| Macchia, G | 2 |
| Deodato, F | 2 |
| Cilla, S | 1 |
| Tagliaferri, L | 1 |
| Cammelli, S | 1 |
| Valentini, V | 2 |
| Morganti, AG | 2 |
| Mattiucci, GC | 2 |
| Gbolahan, O | 1 |
| Hashemi-Sadraei, N | 1 |
| O'Neil, B | 1 |
| Guo, SS | 1 |
| Fan, QX | 1 |
| Sookprasert, A | 2 |
| Pugkhem, A | 2 |
| Khuntikeo, N | 3 |
| Chur-in, S | 1 |
| Chamadol, N | 1 |
| Prawan, A | 3 |
| Janeklang, S | 1 |
| Kukongviriyapan, V | 3 |
| Bhudhisawasdi, V | 2 |
| Min, HS | 1 |
| Han, SW | 3 |
| Im, SA | 3 |
| Kim, TY | 3 |
| Bang, YJ | 3 |
| Jang, JJ | 1 |
| Ha, SW | 3 |
| Lange, S | 1 |
| Lampe, J | 1 |
| Bossow, S | 1 |
| Zimmermann, M | 1 |
| Neubert, W | 1 |
| Bitzer, M | 1 |
| Lauer, UM | 1 |
| Duignan, S | 1 |
| Maguire, D | 1 |
| Ravichand, CS | 1 |
| Geoghegan, J | 1 |
| Hoti, E | 1 |
| Fennelly, D | 1 |
| Armstrong, J | 1 |
| Rock, K | 1 |
| Mohan, H | 1 |
| Traynor, O | 1 |
| Ge, X | 1 |
| Yu, H | 1 |
| Ji, G | 1 |
| Wiazzane, N | 1 |
| Chauffert, B | 1 |
| Ghiringhelli, F | 2 |
| Wirasorn, K | 1 |
| Ngamprasertchai, T | 1 |
| Pakkhem, A | 1 |
| Ungarereevittaya, P | 1 |
| Chindaprasirt, J | 1 |
| Butthongkomvong, K | 1 |
| Sirachainan, E | 1 |
| Jhankumpha, S | 1 |
| Kumdang, S | 1 |
| Sukhontharot, OU | 1 |
| Sinn, M | 1 |
| Nicolaou, A | 1 |
| Ricke, J | 1 |
| Podrabsky, P | 1 |
| Seehofer, D | 1 |
| Gebauer, B | 1 |
| Pech, M | 1 |
| Neuhaus, P | 1 |
| Dörken, B | 2 |
| Riess, H | 2 |
| Hildebrandt, B | 1 |
| Kim, YI | 1 |
| Park, JW | 2 |
| Kim, BH | 1 |
| Woo, SM | 2 |
| Kim, TH | 2 |
| Koh, YH | 2 |
| Lee, WJ | 2 |
| Kim, CM | 2 |
| Zeekpudsa, P | 1 |
| Senggunprai, L | 2 |
| Goldberg, SN | 1 |
| Zhang, F | 1 |
| Le, T | 1 |
| Wu, X | 1 |
| Wang, H | 1 |
| Zhang, T | 1 |
| Meng, Y | 1 |
| Wei, B | 1 |
| Soriano, SS | 1 |
| Willis, P | 1 |
| Kolokythas, O | 1 |
| Yang, X | 1 |
| Takahashi, N | 1 |
| Aoyama, F | 1 |
| Hiyoshi, M | 1 |
| Kataoka, H | 1 |
| Sawaguchi, A | 1 |
| Wu, WR | 1 |
| Zhang, R | 1 |
| Shi, XD | 1 |
| Zhu, MS | 1 |
| Xu, LB | 1 |
| Zeng, H | 1 |
| Kasai, K | 1 |
| Kooka, Y | 1 |
| Suzuki, Y | 1 |
| Suzuki, A | 1 |
| Oikawa, T | 1 |
| Ushio, A | 1 |
| Kasai, Y | 1 |
| Sawara, K | 1 |
| Miyamoto, Y | 1 |
| Oikawa, K | 1 |
| Takikawa, Y | 1 |
| Hong, MJ | 1 |
| Cheon, YK | 1 |
| Lee, EJ | 1 |
| Lee, TY | 1 |
| Shim, CS | 1 |
| Sio, TT | 1 |
| Martenson, JA | 1 |
| Haddock, MG | 1 |
| Novotny, PJ | 1 |
| Gores, GJ | 1 |
| Alberts, SR | 2 |
| Miller, RC | 1 |
| Heimbach, JK | 1 |
| Rosen, CB | 1 |
| Larsen, FO | 1 |
| Mellergaard, AH | 1 |
| Hoegdall, DT | 1 |
| Jensen, LH | 2 |
| Fiteni, F | 1 |
| Jary, M | 1 |
| Monnien, F | 1 |
| Nguyen, T | 1 |
| Beohou, E | 1 |
| Demarchi, M | 1 |
| Dobi, E | 1 |
| Fein, F | 1 |
| Cleau, D | 1 |
| Fratté, S | 1 |
| Nerich, V | 1 |
| Bonnetain, F | 1 |
| Pivot, X | 1 |
| Borg, C | 1 |
| Kim, S | 1 |
| Koido, S | 1 |
| Kan, S | 1 |
| Yoshida, K | 1 |
| Yoshizaki, S | 1 |
| Takakura, K | 1 |
| Namiki, Y | 1 |
| Tsukinaga, S | 1 |
| Odahara, S | 1 |
| Kajihara, M | 1 |
| Okamoto, M | 1 |
| Ito, M | 1 |
| Yusa, S | 1 |
| Gong, J | 1 |
| Sugiyama, H | 1 |
| Ohkusa, T | 1 |
| Homma, S | 1 |
| Tajiri, H | 1 |
| Park, HJ | 1 |
| Patkowski, W | 1 |
| Stankiewicz, R | 1 |
| Grąt, M | 1 |
| Krasnodębski, M | 1 |
| Kornasiewicz, O | 1 |
| Krawczyk, M | 1 |
| Huang, GL | 2 |
| Shen, DY | 2 |
| Cai, CF | 1 |
| Zhang, QY | 1 |
| Ren, HY | 2 |
| Chen, QX | 1 |
| Samatiwat, P | 1 |
| Guion-Dusserre, JF | 1 |
| Lorgis, V | 1 |
| Vincent, J | 1 |
| Bengrine, L | 1 |
| Yashima, Y | 1 |
| Sato, S | 1 |
| Kawai, T | 1 |
| Sugimoto, T | 1 |
| Sato, T | 2 |
| Kanda, M | 1 |
| Obi, S | 1 |
| Ben-Josef, E | 1 |
| Guthrie, KA | 1 |
| El-Khoueiry, AB | 2 |
| Corless, CL | 1 |
| Zalupski, MM | 1 |
| Lowy, AM | 1 |
| Thomas, CR | 1 |
| Dawson, LA | 1 |
| Micetich, KC | 1 |
| Thomas, MB | 1 |
| Siegel, AB | 1 |
| Blanke, CD | 2 |
| Namwat, N | 2 |
| Kanchanawat, S | 1 |
| Jearanaikoon, P | 3 |
| Leelayuwat, C | 2 |
| Techasen, A | 2 |
| Nutthasirikul, N | 1 |
| Limpaiboon, T | 3 |
| Chau-In, S | 1 |
| Massani, M | 1 |
| Nistri, C | 1 |
| Ruffolo, C | 1 |
| Bonariol, R | 1 |
| Pauletti, B | 1 |
| Bonariol, L | 1 |
| Caratozzolo, E | 1 |
| Morana, G | 1 |
| Bassi, N | 1 |
| Sriraksa, R | 1 |
| Fraveto, A | 1 |
| Cardinale, V | 1 |
| Bragazzi, MC | 1 |
| Giuliante, F | 2 |
| De Rose, AM | 1 |
| Grazi, GL | 1 |
| Napoletano, C | 1 |
| Semeraro, R | 1 |
| Lustri, AM | 1 |
| Costantini, D | 1 |
| Nevi, L | 1 |
| Di Matteo, S | 1 |
| Renzi, A | 1 |
| Carpino, G | 1 |
| Gaudio, E | 1 |
| Alvaro, D | 1 |
| Konstantinidis, IT | 1 |
| Groot Koerkamp, B | 1 |
| Do, RK | 1 |
| Gönen, M | 1 |
| Fong, Y | 1 |
| Allen, PJ | 1 |
| D'Angelica, MI | 1 |
| Kingham, TP | 1 |
| DeMatteo, RP | 1 |
| Klimstra, DS | 1 |
| Kemeny, NE | 1 |
| Jarnagin, WR | 1 |
| Kraiklang, R | 1 |
| Umezawa, K | 1 |
| Okada, S | 1 |
| Wentrup, R | 1 |
| Winkelmann, N | 1 |
| Mitroshkin, A | 1 |
| Prager, M | 1 |
| Voderholzer, W | 1 |
| Schachschal, G | 1 |
| Jürgensen, C | 1 |
| Büning, C | 1 |
| Li, H | 2 |
| Jiang, X | 1 |
| Chen, D | 1 |
| Ni, J | 1 |
| Sun, H | 1 |
| Luo, J | 1 |
| Yao, H | 1 |
| Xu, L | 1 |
| Endlicher, E | 1 |
| Schnoy, E | 1 |
| Troppmann, M | 1 |
| Rogler, G | 1 |
| Messmann, H | 1 |
| Klebl, F | 1 |
| Gelbmann, C | 1 |
| Kullmann, F | 1 |
| Chen, B | 2 |
| Liu, Y | 1 |
| Kato, S | 1 |
| Takeuchi, Y | 1 |
| Wada, N | 1 |
| Morimoto, Y | 1 |
| Kuwaki, K | 1 |
| Ohnishi, H | 1 |
| Nakamura, S | 1 |
| Shiraha, H | 1 |
| Takaki, A | 1 |
| Okada, H | 1 |
| Hasuike, Y | 5 |
| Higuchi, I | 1 |
| Hosomi, S | 1 |
| Ishikawa, A | 2 |
| Akiyama, Y | 1 |
| Tanigawa, T | 1 |
| Okada, A | 1 |
| Yu, ZY | 1 |
| Ouyang, XN | 1 |
| Chen, ZS | 1 |
| Li, J | 1 |
| Chen, X | 1 |
| Xie, FW | 1 |
| Nelson, JW | 1 |
| Ghafoori, AP | 1 |
| Willett, CG | 1 |
| Tyler, DS | 1 |
| Pappas, TN | 1 |
| Clary, BM | 1 |
| Hurwitz, HI | 1 |
| Bendell, JC | 1 |
| Morse, MA | 1 |
| Clough, RW | 1 |
| Czito, BG | 1 |
| Gennatas, C | 1 |
| Michalaki, V | 1 |
| Gennatas, S | 1 |
| Lang, M | 1 |
| Henson, R | 2 |
| Braconi, C | 1 |
| Patel, T | 2 |
| Honda, K | 1 |
| Hamada, H | 1 |
| Kobayashi, N | 2 |
| Singal, A | 1 |
| Welling, TH | 1 |
| Marrero, JA | 1 |
| Zygulska, AL | 1 |
| Pawlega, J | 1 |
| Shimoda, M | 1 |
| Sawada, T | 1 |
| Kubota, K | 1 |
| Yamashita, Y | 2 |
| Taketomi, A | 1 |
| Itoh, S | 1 |
| Harimoto, N | 1 |
| Tsujita, E | 1 |
| Sugimachi, K | 1 |
| Gion, T | 1 |
| Maehara, Y | 1 |
| Wagner, AD | 1 |
| Buechner-Steudel, P | 1 |
| Moehler, M | 1 |
| Schmalenberg, H | 1 |
| Behrens, R | 1 |
| Fahlke, J | 1 |
| Wein, A | 1 |
| Behl, S | 1 |
| Kuss, O | 1 |
| Kleber, G | 1 |
| Fleig, WE | 1 |
| Hatano, H | 1 |
| Nagano, H | 5 |
| Tomokuni, A | 1 |
| Tomimaru, Y | 2 |
| Murakami, M | 1 |
| Marubashi, S | 2 |
| Eguchi, H | 2 |
| Takeda, Y | 2 |
| Tanemura, M | 1 |
| Wakasa, K | 1 |
| Doki, Y | 2 |
| Mori, M | 2 |
| Yokoo, H | 1 |
| Kamiyama, T | 1 |
| Nakagawa, T | 1 |
| Nakanishi, K | 1 |
| Tahara, M | 1 |
| Fukumori, D | 1 |
| Kamachi, H | 1 |
| Matsushita, M | 1 |
| Todo, S | 1 |
| Gerhardt, T | 1 |
| Rings, D | 1 |
| Höblinger, A | 1 |
| Heller, J | 1 |
| Sauerbruch, T | 1 |
| Schepke, M | 1 |
| Louvet, C | 1 |
| Tournigand, C | 1 |
| Chang, PY | 1 |
| Cheng, MF | 1 |
| Lee, HS | 1 |
| Hsieh, CB | 2 |
| Yao, NS | 1 |
| Kruth, J | 1 |
| Nissen, J | 1 |
| Ernst, T | 1 |
| Kripp, M | 1 |
| Lukan, N | 1 |
| Merx, K | 1 |
| Hofmann, WK | 1 |
| Hochhaus, A | 1 |
| Hofheinz, RD | 1 |
| Thanasai, J | 1 |
| Tantimavanich, S | 1 |
| Miwa, M | 1 |
| Nagai, K | 1 |
| Ishii, H | 1 |
| Miyoshi, N | 1 |
| Hoshino, H | 1 |
| Saito, T | 1 |
| Sekimoto, M | 1 |
| Yürek, S | 1 |
| Kreher, S | 1 |
| Salama, A | 1 |
| Park, JH | 1 |
| Choi, EK | 1 |
| Ahn, SD | 1 |
| Lee, SW | 1 |
| Song, SY | 1 |
| Yoon, SM | 1 |
| Kim, YS | 1 |
| Lee, YS | 1 |
| Lee, SG | 1 |
| Hwang, S | 1 |
| Lee, YJ | 1 |
| Park, KM | 1 |
| Kim, TW | 2 |
| Chang, HM | 2 |
| Lee, JL | 1 |
| Lassen, U | 1 |
| Sorensen, M | 1 |
| Rohrberg, KS | 1 |
| Ujmajuridze, Z | 1 |
| Jakobsen, A | 1 |
| Abahssain, H | 1 |
| Afchain, P | 1 |
| Melas, N | 1 |
| Ismaili, N | 1 |
| Rahali, R | 1 |
| Rabti, HM | 1 |
| Errihani, H | 1 |
| Ishibashi, H | 1 |
| Utsunomiya, T | 1 |
| Ochir, TL | 1 |
| Hanaoka, J | 1 |
| Mori, H | 2 |
| Iqbal, S | 1 |
| Rankin, C | 1 |
| Lenz, HJ | 1 |
| Gold, PJ | 1 |
| Ahmad, SA | 1 |
| Messino, MJ | 1 |
| Holcombe, RF | 1 |
| Kitahara, H | 1 |
| Masumoto, J | 1 |
| Parker, AL | 1 |
| Maruta, F | 1 |
| Kubo, N | 1 |
| Shimizu, A | 1 |
| Akita, N | 1 |
| Miwa, S | 1 |
| Nakayama, J | 1 |
| Miyagawa, S | 1 |
| Gringeri, E | 1 |
| Bassi, D | 1 |
| D'Amico, FE | 1 |
| Boetto, R | 1 |
| Polacco, M | 1 |
| Lodo, E | 1 |
| D'Amico, F | 1 |
| Vitale, A | 1 |
| Boccagni, P | 1 |
| Zanus, G | 1 |
| Cillo, U | 1 |
| Bonet Beltrán, M | 1 |
| Roth, AD | 1 |
| Mentha, G | 1 |
| Allal, AS | 1 |
| Tani, S | 1 |
| Murata, S | 1 |
| Tamura, M | 1 |
| Fukunaga, K | 1 |
| Morita, M | 1 |
| Hirata, Y | 1 |
| Iida, H | 1 |
| Kakuno, A | 1 |
| Nishigami, T | 1 |
| Yoon, JY | 1 |
| Nam, TS | 1 |
| Kim, MK | 1 |
| Hwang, JE | 1 |
| Shim, HJ | 1 |
| Cho, SH | 1 |
| Chung, IJ | 1 |
| Bae, WK | 1 |
| Pracht, M | 1 |
| Le Roux, G | 1 |
| Sulpice, L | 1 |
| Mesbah, H | 1 |
| Audrain, O | 1 |
| Boudjema, K | 1 |
| Raoul, JL | 1 |
| Boucher, E | 1 |
| Han, SS | 1 |
| Park, SJ | 1 |
| Kim, HB | 1 |
| Hong, EK | 1 |
| Nonaka, Y | 1 |
| Nanashima, A | 1 |
| Nonaka, T | 1 |
| Uehara, M | 1 |
| Isomoto, H | 1 |
| Abo, T | 1 |
| Nagayasu, T | 1 |
| Chaiyagool, J | 1 |
| Tassaneeyakul, W | 1 |
| Croitoru, A | 1 |
| Gramaticu, I | 1 |
| Dinu, I | 1 |
| Gheorghe, L | 1 |
| Alexandrescu, S | 1 |
| Buica, F | 1 |
| Luca, I | 1 |
| Becheanu, G | 1 |
| Herlea, V | 1 |
| Simionov, I | 1 |
| Hrehoret, D | 1 |
| Lupescu, I | 1 |
| Popescu, I | 1 |
| Diculescu, M | 1 |
| Turaga, KK | 1 |
| Tsai, S | 1 |
| Wiebe, LA | 1 |
| Evans, DB | 1 |
| Gamblin, TC | 1 |
| Knox, JJ | 3 |
| Iwagami, Y | 1 |
| Kira, T | 1 |
| Hirao, S | 1 |
| Komatsu, H | 1 |
| Kanazawa, A | 1 |
| Tsukamoto, T | 1 |
| Shimizu, S | 1 |
| Mori, Y | 2 |
| Ohira, G | 1 |
| Kodai, S | 1 |
| Morimoto, J | 1 |
| Yamazoe, S | 1 |
| Yamamoto, A | 1 |
| Inoue, T | 1 |
| Nishiguchi, Y | 1 |
| Ikehara, T | 1 |
| Taira, K | 1 |
| Horii, K | 1 |
| Yamazaki, O | 1 |
| Gardini, A | 1 |
| Saragoni, L | 1 |
| La Barba, G | 1 |
| Serra, L | 1 |
| Calistri, D | 1 |
| Ulivi, P | 1 |
| Casadei, A | 1 |
| Frassineti, GL | 1 |
| Garcea, D | 1 |
| Sudan, D | 1 |
| DeRoover, A | 1 |
| Chinnakotla, S | 1 |
| Fox, I | 1 |
| Shaw, B | 1 |
| McCashland, T | 1 |
| Sorrell, M | 1 |
| Tempero, M | 1 |
| Langnas, A | 1 |
| Takada, T | 2 |
| Amano, H | 1 |
| Yasuda, H | 2 |
| Nimura, Y | 1 |
| Matsushiro, T | 1 |
| Kato, H | 1 |
| Nagakawa, T | 1 |
| Nakayama, T | 1 |
| Schleicher, UM | 1 |
| Staatz, G | 1 |
| Alzen, G | 1 |
| Andreopoulos, D | 1 |
| Kang, HJ | 1 |
| Lee, JR | 1 |
| Ryu, MH | 1 |
| Ahn, JH | 1 |
| Kang, YK | 1 |
| SULLIVAN, RD | 1 |
| NORCROSS, JW | 1 |
| WATKINS, E | 1 |
| FIELD, JB | 1 |
| Hedley, D | 1 |
| Oza, A | 1 |
| Siu, LL | 1 |
| Pond, GR | 2 |
| Moore, MJ | 1 |
| Milano, MT | 1 |
| Chmura, SJ | 1 |
| Garofalo, MC | 1 |
| Rash, C | 1 |
| Roeske, JC | 1 |
| Connell, PP | 1 |
| Kwon, OH | 1 |
| Jani, AB | 1 |
| Heimann, R | 1 |
| Matsumoto, S | 1 |
| Kiyosue, H | 1 |
| Komatsu, E | 1 |
| Wakisaka, M | 1 |
| Tomonari, K | 1 |
| Hori, Y | 1 |
| Matsumoto, A | 1 |
| Delaunoit, T | 1 |
| Maréchal, R | 1 |
| Hendlisz, A | 1 |
| Eisendrath, P | 1 |
| Legendre, H | 1 |
| Pector, JC | 1 |
| De Becker, D | 1 |
| Bleiberg, H | 1 |
| Patt, YZ | 2 |
| Hassan, MM | 1 |
| Aguayo, A | 1 |
| Nooka, AK | 1 |
| Lozano, RD | 1 |
| Curley, SA | 1 |
| Vauthey, JN | 2 |
| Ellis, LM | 1 |
| Schnirer, II | 1 |
| Wolff, RA | 1 |
| Charnsangavej, C | 3 |
| Brown, TD | 1 |
| Kelley, ST | 1 |
| Bloomston, M | 1 |
| Serafini, F | 1 |
| Carey, LC | 1 |
| Karl, RC | 1 |
| Zervos, E | 1 |
| Goldin, S | 1 |
| Rosemurgy, P | 1 |
| Rosemurgy, AS | 1 |
| Wada, H | 2 |
| Dono, K | 1 |
| Kondo, M | 1 |
| Yamamoto, T | 1 |
| Ota, H | 1 |
| Nakamura, M | 1 |
| Yoshioka, S | 1 |
| Damdinsuren, B | 1 |
| Yubo, Y | 1 |
| Miyamoto, A | 1 |
| Umeshita, K | 1 |
| Nakamori, S | 2 |
| Sakon, M | 1 |
| Monden, M | 1 |
| Kashiwazaki, M | 1 |
| Tsujinaka, T | 1 |
| Brunner, TB | 1 |
| Schwab, D | 1 |
| Meyer, T | 1 |
| Sauer, R | 1 |
| Kamisawa, T | 2 |
| Tu, Y | 2 |
| Egawa, N | 2 |
| Karasawa, K | 1 |
| Matsuda, T | 1 |
| Tsuruta, K | 1 |
| Okamoto, A | 2 |
| Clemente, G | 1 |
| Costamagna, G | 1 |
| Smaniotto, D | 1 |
| Luzi, S | 1 |
| Nuzzo, G | 1 |
| Cellini, N | 1 |
| Oda, A | 2 |
| Katayose, Y | 2 |
| Rikiyama, T | 2 |
| Oikawa, M | 2 |
| Yamamoto, K | 1 |
| Unno, M | 2 |
| Akita, H | 1 |
| Yamada, T | 1 |
| Sasaki, Y | 4 |
| Ohigashi, H | 3 |
| Ishikawa, O | 4 |
| Imaoka, S | 4 |
| Hayashi, N | 1 |
| Fukuchi, N | 1 |
| Kida, H | 1 |
| Tujie, M | 1 |
| Yoshida, T | 2 |
| Ebisui, C | 1 |
| Sakita, I | 1 |
| Koshino, T | 1 |
| Izumiyama, K | 1 |
| Koro, T | 1 |
| Fujimoto, T | 1 |
| Sasaki, T | 2 |
| Itoh, Y | 1 |
| Mizushima, T | 1 |
| Sugiura, T | 1 |
| Hori, S | 1 |
| Ito, T | 1 |
| Mizuno, H | 1 |
| Hoki, M | 1 |
| Souma, Y | 1 |
| Kainuma, S | 1 |
| Yamanaka, H | 1 |
| Ozawa, H | 1 |
| Kanou, T | 1 |
| Nakamori, Y | 1 |
| Iwase, K | 1 |
| Kobayashi, K | 1 |
| Tsuji, A | 1 |
| Morita, S | 1 |
| Horimi, T | 1 |
| Shirasaka, T | 1 |
| Kanematsu, T | 1 |
| Naus, PJ | 1 |
| Bleeker, G | 1 |
| Wehbe, H | 1 |
| Meng, F | 1 |
| Nishizawa, T | 1 |
| Higuchi, H | 1 |
| Takaishi, H | 1 |
| Iizuka, H | 1 |
| Izumiya, M | 1 |
| Yamagishi, Y | 1 |
| Hisamatsu, T | 1 |
| Suzuki, H | 2 |
| Masaoka, T | 1 |
| Iwasaki, E | 1 |
| Nagata, H | 1 |
| Hibi, T | 1 |
| Schoppmeyer, K | 1 |
| Miethe, S | 1 |
| Wiedmann, M | 1 |
| Liebmann, A | 1 |
| Hauss, J | 1 |
| Mossner, J | 1 |
| Caca, K | 1 |
| Witzigmann, H | 1 |
| Hildebrandt, G | 1 |
| Mizumoto, T | 1 |
| Masuda, T | 1 |
| Okabe, K | 1 |
| Baba, Y | 1 |
| Okabe, H | 1 |
| Takamori, H | 1 |
| Kanemitsu, K | 1 |
| Hiroto, M | 1 |
| Huang, TW | 1 |
| Wang, CH | 1 |
| Slupski, MW | 1 |
| Szczylik, C | 1 |
| Jasinski, MK | 1 |
| Tang, T | 1 |
| Zheng, JW | 1 |
| Li, X | 1 |
| Xue, KY | 1 |
| Ai, X | 1 |
| Zou, SQ | 1 |
| Riechelmann, RP | 1 |
| Townsley, CA | 1 |
| Chin, SN | 1 |
| Iyer, RV | 1 |
| Gibbs, J | 1 |
| Kuvshinoff, B | 1 |
| Fakih, M | 1 |
| Kepner, J | 1 |
| Soehnlein, N | 1 |
| Lawrence, D | 1 |
| Javle, MM | 1 |
| Sugimoto, K | 1 |
| Nakahira, S | 1 |
| Miki, H | 1 |
| Nakata, K | 1 |
| Okamura, S | 1 |
| Okada, K | 1 |
| Miyake, T | 1 |
| Yoshimura, M | 1 |
| Uji, K | 1 |
| Yoshida, A | 1 |
| Suzuki, R | 1 |
| Komori, M | 1 |
| Tamura, S | 1 |
| Smith, GW | 1 |
| Bukowski, RM | 2 |
| Hewlett, JS | 2 |
| Groppe, CW | 2 |
| Hashmonai, M | 1 |
| Lev, L | 1 |
| Schramek, A | 1 |
| Ben-Arieh, Y | 1 |
| Robinson, E | 1 |
| Beals, SP | 1 |
| Lucas, RJ | 1 |
| Falkson, G | 1 |
| MacIntyre, JM | 1 |
| Moertel, CG | 1 |
| Buskirk, SJ | 2 |
| Gunderson, LL | 2 |
| Adson, MA | 1 |
| Martinez, A | 1 |
| May, GR | 1 |
| McIlrath, DC | 2 |
| Nagorney, DM | 1 |
| Edmundson, GK | 1 |
| Bender, CE | 2 |
| Martin, JK | 2 |
| Kikuchi, K | 1 |
| Kelm, C | 1 |
| Henneking, K | 1 |
| Zimmermann, T | 1 |
| Vollerthun, M | 1 |
| Padberg, W | 1 |
| Whittington, R | 1 |
| Neuberg, D | 1 |
| Tester, WJ | 1 |
| Benson, AB | 1 |
| Haller, DG | 1 |
| Tsuji, Y | 1 |
| Imai, M | 1 |
| Katsuki, Y | 1 |
| Yasuda, T | 3 |
| Nishimura, A | 1 |
| Kajanti, M | 1 |
| Pyrhönen, S | 1 |
| Hsue, V | 1 |
| Wong, CS | 1 |
| Moore, M | 1 |
| Erlichman, C | 1 |
| Cummings, BJ | 1 |
| MacLeod, M | 1 |
| Jones, DV | 1 |
| Hoque, A | 1 |
| Lozano, R | 1 |
| Markowitz, A | 1 |
| Raijman, I | 1 |
| Lynch, P | 1 |
| Nakano, H | 1 |
| Furukawa, H | 3 |
| Kabuto, T | 2 |
| Kameyama, M | 1 |
| Hiratsuka, M | 1 |
| Iwanaga, T | 1 |
| Muto, A | 1 |
| Ashino, Y | 1 |
| Ito, H | 1 |
| Kanno, A | 1 |
| Moriyama, A | 1 |
| Hiraga, M | 1 |
| Pederson, LC | 1 |
| Buchsbaum, DJ | 1 |
| Vickers, SM | 1 |
| Kancharla, SR | 1 |
| Mayo, MS | 1 |
| Curiel, DT | 1 |
| Stackhouse, MA | 1 |
| Sanz-Altamira, PM | 1 |
| Ferrante, K | 1 |
| Jenkins, RL | 1 |
| Lewis, WD | 1 |
| Huberman, MS | 1 |
| Stuart, KE | 1 |
| Marvin, MR | 1 |
| Lefkowitch, J | 1 |
| Ishak, KG | 1 |
| Chabot, J | 1 |
| Motoori, M | 1 |
| Hattori, T | 1 |
| Fujita, J | 1 |
| Mishima, H | 1 |
| Sawamura, T | 1 |
| Nishishou, I | 1 |
| Kikkawa, N | 1 |
| Sai, H | 1 |
| Hosoki, T | 1 |
| Mitomo, M | 1 |
| Kitagawa, K | 1 |
| Taniguchi, H | 1 |
| Koh, T | 1 |
| Ohbayashi, T | 1 |
| Kunishima, S | 1 |
| Yamaguchi, A | 1 |
| Masuyama, M | 1 |
| Kitamura, K | 1 |
| Hagiwara, A | 1 |
| Yamaguchi, T | 1 |
| Yamagishi, H | 1 |
| Lo, SS | 1 |
| Wu, CW | 1 |
| Chi, KH | 1 |
| Tseng, HS | 1 |
| Shen, KH | 1 |
| Hsieh, MC | 1 |
| Lui, WY | 1 |
| Nakagami, K | 1 |
| Takahashi, T | 1 |
| Sugitani, K | 1 |
| Yokomori, T | 1 |
| Iesato, H | 1 |
| Ohya, T | 1 |
| Ohwada, S | 1 |
| Morishita, Y | 1 |
| Goulart, BH | 1 |
| Martins, RG | 1 |
| Lynch, TJ | 1 |
| Tanaka, N | 1 |
| Yamakado, K | 1 |
| Nakatsuka, A | 1 |
| Fujii, A | 1 |
| Matsumura, K | 1 |
| Takeda, K | 1 |
| Matsumoto, T | 1 |
| Sasaki, A | 1 |
| Morii, Y | 1 |
| Aramaki, M | 1 |
| Kitano, S | 1 |
| Bouras, N | 1 |
| Caudry, M | 1 |
| Saric, J | 1 |
| Bonnel, C | 1 |
| Rullier, E | 1 |
| Trouette, R | 1 |
| Demeaux, H | 1 |
| Maire, JP | 1 |
| Stemmler, J | 1 |
| Heinemann, V | 1 |
| Schalhorn, A | 1 |
| Crane, CH | 1 |
| Macdonald, KO | 1 |
| Yehuda, P | 1 |
| Brown, T | 1 |
| Curley, S | 1 |
| Wong, A | 1 |
| Delclos, M | 1 |
| Janjan, NA | 1 |
| Balasegaram, M | 1 |
| Black, K | 1 |
| Hanna, SS | 1 |
| Langer, B | 2 |
| Jirsch, DW | 1 |
| Rider, WD | 1 |
| Chevrel, JP | 1 |
| Damsin, JP | 1 |
| Lebhar, E | 1 |
| Seligman, M | 1 |
| Weick, JK | 1 |
| Greenstreet, RL | 1 |
| Ingis, DA | 1 |
| Farmer, RG | 1 |
| Hara, Y | 1 |
| Tobita, Y | 1 |
| Falk, RE | 1 |
| MacGregor, AB | 1 |
| Landi, S | 1 |
| Ambus, U | 1 |
| Schild, SE | 1 |
| Williams, HJ | 1 |
| Robinow, JS | 1 |
| Tremaine, WJ | 1 |
| Tsushima, K | 2 |
| Sakata, Y | 2 |
| Shiratori, Y | 1 |
| Sakamoto, J | 1 |
| Koeda, J | 1 |
| Yamada, Y | 1 |
| Soma, N | 1 |
| Tamura, K | 1 |
| Yoshiwara, A | 1 |
| Soma, Y | 1 |
| Loreggian, L | 1 |
| Zorat, PL | 1 |
| Lora, O | 1 |
| Fornasiero, A | 1 |
| Calzavara, F | 1 |
| Masutani, S | 1 |
| Ohashi, I | 1 |
| Oohigashi, H | 1 |
| Fukuda, I | 2 |
| Senzer, NN | 1 |
| Stone, MJ | 1 |
| Klintmalm, GB | 1 |
| Polter, D | 1 |
| Schmeck, HJ | 1 |
| Bartels, E | 1 |
| Viets, CH | 1 |
| Arnold, W | 1 |
| Shibata, T | 1 |
| Izumi, R | 1 |
| Urade, M | 1 |
| Kimura, H | 1 |
| Kobayashi, M | 1 |
| Yabushita, K | 1 |
| Watanabe, T | 1 |
| Fujimura, T | 1 |
| Ohhori, I | 1 |
| Itoh, M | 1 |
| Yonemura, Y | 1 |
| Takasaki, H | 1 |
| Uchida, Y | 1 |
| Shigemitsu, O | 1 |
| Oka, K | 1 |
| Fujitomi, Y | 1 |
| Ichimanda, M | 1 |
| Shibata, O | 1 |
| Shirabe, J | 1 |
| Mergenthaler, HG | 1 |
| Binsack, T | 1 |
| Wilmanns, W | 1 |
| Uchiyama, K | 1 |
| Hasegawa, H | 1 |
| Tsuchiya, S | 1 |
| Misu, Y | 1 |
| Saitoh, Y | 1 |
| Shikata, J | 1 |
| Kozakai, M | 1 |
| Fukushi, G | 1 |
| Kimura, T | 1 |
| Kimura, M | 1 |
| Tamura, Y | 1 |
| Kishibe, T | 1 |
| Saitoh, S | 1 |
| Itoh, T | 1 |
| Dobelbower, RR | 1 |
| Merrick, HW | 1 |
| Ahuja, RK | 1 |
| Skeel, RT | 1 |
| Massey, WH | 1 |
| Fletcher, WS | 1 |
| Judkins, MP | 1 |
| Dennis, DL | 1 |
| Futorian, ES | 2 |
| Shubin, BM | 2 |
| Griffen, WO | 1 |
| Humphrey, L | 1 |
| Sosin, H | 1 |
| Davis, HL | 1 |
| Ramirez, G | 1 |
| Ansfield, FJ | 1 |
| Sanderson, TA | 1 |
| McBride, CM | 1 |
| Gordon, B | 1 |
| Shaw, BW | 1 |
| Roszmann, MH | 1 |
| Lazichev, IuD | 1 |
| Nadler, SH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Endobiliary Radiofrequency Ablation With S-1 in Patients With Unresectable Cholangiocarcinoma: A Prospective Randomized Trial With Open Label Control[NCT02592538] | 66 participants (Actual) | Interventional | 2015-12-31 | Completed | |||
| A Clinical Trial Phase II of Calcitriol in Combination With 5-fluorouracil, Mitomycin C and Leucovorin in an Open Label-non-randomized Study to Evaluate the Tumor Response in Patients With Advanced Intrahepatic Cholangiocarcinoma[NCT01039181] | Phase 2 | 28 participants (Anticipated) | Interventional | 2010-01-31 | Not yet recruiting | ||
| A Phase 2 Study of Low-Dose Fractionated Radiation Therapy to the Whole Liver in Combination With Gemcitabine and Cisplatin in Locally Advanced Mass-Forming Intrahepatic Cholangiocarcinoma[NCT02254681] | Phase 2 | 6 participants (Actual) | Interventional | 2014-09-30 | Terminated (stopped due to lack of funding) | ||
| Efficacy and Safety of Trifluridine/Tipiracil in Combination With Irinotecan as a Second Line Therapy in Patients With Cholangiocarcinoma[NCT04059562] | Phase 2 | 28 participants (Anticipated) | Interventional | 2021-10-28 | Active, not recruiting | ||
| A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed By Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC)[NCT00789958] | Phase 2 | 105 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| A Randomized Controlled, Open Labeled, Two Arm, Study of Addition of Everolimus to Standard of Care in Carcinoma Gallbladder[NCT05833815] | Phase 2/Phase 3 | 56 participants (Anticipated) | Interventional | 2022-11-01 | Recruiting | ||
| Efficacy and Tolerance of RADIOEMBOLIZATION for Patients With Unresectable Intrahepatic Cholangiocarcinoma With Tumor Progression After First-line Therapy[NCT01383746] | Phase 1/Phase 2 | 5 participants (Actual) | Interventional | 2011-10-31 | Terminated (stopped due to Not enough inclusion) | ||
| A Phase II Trial of Gemcitabine (NSC-613327) and Capecitabine (NSC-712807) in Patients With Unresectable or Metastatic Gallbladder or Cholangiocarcinoma[NCT00033540] | Phase 2 | 57 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
| Prospective Registry Study of Neoadjuvant Therapy in Conjunction With Liver Transplantation for Cholangiocarcinoma[NCT00301379] | 59 participants (Actual) | Observational | 2005-08-12 | Terminated (stopped due to Low accrual) | |||
| A Single-Arm Nonrandomized Phase II Study of Liver Transplantation in Locally Advanced Unresectable Non-Metastatic Intrahepatic Cholangiocarcinoma Treated With Neoadjuvant Systemic Therapy[NCT06140134] | 30 participants (Anticipated) | Observational [Patient Registry] | 2023-12-31 | Not yet recruiting | |||
| Randomized Controlled Trial Comparing Adjuvant Chemotherapy Vs. no Chemotherapy for Patients With Carcinoma of Gallbladder Undergoing Curative Resection.[NCT02778308] | 100 participants (Actual) | Interventional | 2012-01-31 | Completed | |||
| Randomized Phase 2 Study of Capecitabine vs Gemcistabine Plus Cisplatin in Patients With Resected Extrahepatic Cholangiocarcinoma With Regional Lymph Node Metastasis[NCT03079427] | Phase 2 | 101 participants (Actual) | Interventional | 2017-05-15 | Completed | ||
| Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.[NCT02595320] | Phase 2 | 200 participants (Actual) | Interventional | 2015-10-05 | Active, not recruiting | ||
| Oxaliplatin Plus Gemcitabine Versus Capecitabine Alone as Adjuvant Treatment in the Prevention of Recurrence of Intrahepatic Cholangiocarcinoma[NCT02548195] | Phase 3 | 286 participants (Anticipated) | Interventional | 2015-07-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To determine the number of participants with Intrahepatic disease progression assessed by MRI of the abdomen with intravenous gadolinium contrast using RECIST criteria. (NCT02254681)
Timeframe: From date of first treatment until date of first documented progression or date of death from any cause, which ever comes first, assessed up to 24 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 6 |
To determine the number of participants with Intrahepatic recurrence assessed by RECIST criteria using MRI of the abdomen with intravenous gadolinium contrast. (NCT02254681)
Timeframe: From date of partial hepatectomy until date of first documented recurrence or date of death from any cause, assessed up to 24 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 1 |
Measured post-operative complications include (but not limited to) bile leak, liver failure, ascites, infection, any organ failure or insufficiency, venous thromboembolism, and mortality. (NCT02254681)
Timeframe: up to 90 days after partial hepatectomy
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 1 |
Disease-free survival is calculated from date of registration to date of first documentation of relapse or death due to any cause. Patients last known to be alive are censored at date of last contact. (NCT00789958)
Timeframe: Up to 2 years from registration
| Intervention | percentage of participants (Number) |
|---|---|
| Adjuvant Chemotherapy + Chemoradiotherapy | 52 |
Local relapse is any evidence of new disease within the primary tumor bed or the regional (retroperitoneal, celiac, and portal vein nodes) lymphatics (these areas are to be encompassed within the radiation fields). (NCT00789958)
Timeframe: Up to 2 years from registration
| Intervention | percentage of participants (Number) |
|---|---|
| Adjuvant Chemotherapy + Chemoradiotherapy | 11 |
Time to death is calculated from date of registration to date of death due to any cause. Patients last known to be alive are censored at date of last contact. (NCT00789958)
Timeframe: Up to 2 years from registration
| Intervention | percentage of participants (Number) |
|---|---|
| Adjuvant Chemotherapy + Chemoradiotherapy | 65 |
Disease-free survival is calculated from date of registration to date of first documentation of relapse or death due to any cause. Patients last known to be alive are censored at date of last contact. (NCT00789958)
Timeframe: Up to 2 years from registration
| Intervention | percentage of participants (Number) |
|---|---|
| Patients With Negative Margins of Resection (R0) | 54 |
| Patients w/Microscopically Positive Margin of Resection (R1) | 48 |
Local relapse is any evidence of new disease within the primary tumor bed or the regional (retroperitoneal, celiac, and portal vein nodes) lymphatics (these areas are to be encompassed within the radiation fields). (NCT00789958)
Timeframe: Up to 2 years from registration
| Intervention | percentage of participants (Number) |
|---|---|
| Patients With Negative Margins of Resection (R0) | 9 |
| Patients w/Microscopically Positive Margin of Resection (R1) | 16 |
Time to death is calculated from date of registration to date of death due to any cause. Patients last known to be alive are censored at date of last contact. (NCT00789958)
Timeframe: Up to 2 years from registration
| Intervention | percentage of participants (Number) |
|---|---|
| Patients With Negative Margins of Resection (R0) | 67 |
| Patients w/Microscopically Positive Margin of Resection (R1) | 60 |
Only adverse events that are possibly, probably or definitely related to study drug are reported. (NCT00789958)
Timeframe: Up to 5 years
| Intervention | Participants (Number) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anorexia | Cardiac troponin I (cTnI) | Constipation | Dehydration | Diarrhea | Fatigue (asthenia, lethargy, malaise) | Febrile neutropenia | Hemoglobin | Hemorrhage, GI - Duodenum | Hemorrhage, GI - Lower GI NOS | Hypotension | Lung Infection w/normal ANC or Gr 1-2 neutrophils | Skin Infection w/normal ANC or Gr 1-2 neutrophils | Infection-Other (Specify) | Leukocytes (total WBC) | Lymphopenia | Mucositis/stomatitis (clinical exam) - Oral cavity | Neuropathy: sensory | Neutrophils/granulocytes (ANC/AGC) | Phosphate, serum-low (hypophosphatemia) | Platelets | Potassium, serum-low (hypokalemia) | Rash/desquamation | Rash: hand-foot skin reaction | Sodium, serum-low (hyponatremia) | Syncope (fainting) | Thrombosis/embolism (vascular access-related) | Thrombosis/thrombus/embolism | Ulcer, GI - Duodenum | Ventricular arrhythmia - Ventricular tachycardia | |
| Adjuvant Chemotherapy + Chemoradiotherapy | 1 | 1 | 1 | 1 | 6 | 4 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 6 | 2 | 1 | 35 | 1 | 2 | 2 | 1 | 10 | 1 | 1 | 1 | 1 | 1 | 1 |
Measured from time of registration to death, or last contact date (NCT00033540)
Timeframe: All patients will be followed until death or three years after registration, whichever is first.
| Intervention | months (Median) |
|---|---|
| Capecitabine + Gemcitabine | 7 |
Only eligible patients who received treatment were evaluable for response and survival outcomes. (NCT00033540)
Timeframe: 1-20 months
| Intervention | participants (Number) | |
|---|---|---|
| Eligible | Eligible and Analyzable | |
| Capecitabine + Gemcitabine | 54 | 52 |
To evaluate in a preliminary fashion relevant prognostic markers in gallbladder and cholangiocarcinoma which may have prognostic implications as predictors of survival. Overall survival measured from time of registration to death, or last contact date. (NCT00033540)
Timeframe: All patients will be followed until death or three years after registration, whichever is first.
| Intervention | months (Median) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TS 3' +/+ (N=14) | TS 3' +/- (N=6) | TS 3' -/- (N=2) | TS 5' Low functional significance (N=16) | TS 5' Intermediate functional significance (N=16) | MTHFR C677T - C/C (N=11) | MTHFR C677T - C/T (N=11) | MTHFR A1298C - A/A (N=11) | MTHFR A1298C - A/C (N=8) | MTHFR A1298C - C/C (N=3) | RRMI G/A - G/G (N=9) | RRMI G/A - G/A (N=10) | RRMI G/A - A/A (N=3) | CDA A79C - A/A (N=8) | CDA A79C - A/C (N=12) | CDA A79C - C/C (N=1) | |
| Capecitabine + Gemcitabine | 7 | 7 | 9 | 9 | 7 | 6 | 7 | 7 | 4 | 9 | 7 | 9 | 5 | 4 | 7 | NA |
Adverse Events (AEs) are reported by the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0. Any CTCAE 3.0 event of Grade 3 (severe), Grade 4 (life threatening) or Grade 5 (fatal) which were deemed to be related to protocol treatment are included. For each patient, worst grade of each event type is reported. (NCT00033540)
Timeframe: Patients were assessed for adverse events 3 weeks after starting treatment. Assessments for adverse events continued every 3 weeks for the duration of protocol treatment.
| Intervention | Participants (Number) | |||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALT, SGPT (serum glutamic pyruvic transaminase) | AST,SGOT (serum glutamic oxaloacetic transaminase) | Albumin, serum-low (hypoalbuminemia) | Alkaline phosphatase | Anorexia | Ascites (non-malignant) | Bilirubin (hyperbilirubinemia) | Constipation | Creatinine | Dehydration | Diarrhea | Dysphagia (difficulty swallowing) | Fatigue (asthenia, lethargy, malaise) | Hemoglobin | Hemolysis | Hemorrhage, GI - Esophagus | Infection w/Grade 3-4 neutrophils - Upper airway | Infection with normal ANC or Grade 1-2 neutrophils | Leukocytes (total WBC) | Mucositis/stomatitis (clinical exam) - Oral cavity | Mucositis/stomatitis (function/symp)-Oral cavity | Muscle weakness (not due to neuropathy) | Nausea | Neutrophils/granulocytes (ANC/AGC) | Pain - Abdomen NOS | Pain - Joint | Pain - Muscle | Pain - Tumor pain | Platelets | Potassium, serum-low (hypokalemia) | Rash: hand-foot skin reaction | Supraventricular nodal arrhythmia | Thrombosis/thrombus/embolism | Vomiting | |
| Gemcitabine and Capecitabine | 1 | 5 | 1 | 5 | 2 | 1 | 4 | 1 | 1 | 3 | 1 | 1 | 8 | 6 | 1 | 1 | 1 | 1 | 9 | 1 | 1 | 1 | 3 | 16 | 2 | 1 | 1 | 1 | 12 | 2 | 4 | 1 | 1 | 2 |
Complete Response (CR) is complete disappearance of all measurable and non-measurable disease. No new lesions, no disease related symptoms. Normalization of markers and other abnormal lab values. Partial Response (PR) is greater than or equal to 30% decrease under baseline of the sum of longest diameters of all target measurable lesions. No unequivocal progression of non-measurable disease. No new lesions. Confirmation of CR or PR means a repeat scan at least 4 weeks apart documented before progression or symptomatic deterioration. Progression is 20% increase in sum of longest diameters of target measurable lesions over smallest sum observed and/or unequivocal progression of non-measurable disease and/or appearance of new lesion/site or death due to disease without prior documentation of progression and without symptomatic deterioration. Symptomatic deterioration is global deterioration of health status requiring discontinuation of treatment without objective evidence of progression. (NCT00033540)
Timeframe: Patients assessed at least every six weeks while on protocol treatment
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Confirmed Partial Response | Unconfirmed Partial Response | Stable Disease | Progression | Symptomatic Deterioration | Early Death | Inadequate Assessment | |
| Capecitabine + Gemcitabine | 7 | 6 | 12 | 15 | 3 | 1 | 8 |
12 reviews available for fluorouracil and Bile Duct Neoplasms
| Article | Year |
|---|---|
Cholangiocarcinoma: what are the options in all comers and how has the advent of molecular profiling opened the way to personalised medicine ?
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Fluorouracil; Humans; Precision M | 2023 |
Cholangiocarcinoma: what are the options in all comers and how has the advent of molecular profiling opened the way to personalised medicine ?
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Fluorouracil; Humans; Precision M | 2023 |
Cholangiocarcinoma: what are the options in all comers and how has the advent of molecular profiling opened the way to personalised medicine ?
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Fluorouracil; Humans; Precision M | 2023 |
Cholangiocarcinoma: what are the options in all comers and how has the advent of molecular profiling opened the way to personalised medicine ?
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Fluorouracil; Humans; Precision M | 2023 |
The efficacy and safety of 5-fluorouracil based adjuvant therapy in resected biliary tract cancer: A systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Bilia | 2022 |
Intrahepatic chemotherapy for unresectable cholangiocarcinoma: review of literature and personal experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cholangiocarcinoma | 2015 |
A case of unresectable combined hepatocellular cholangiocarcinoma showing favorable response to LFP therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma, Hepatocellular; Chol | 2016 |
The role of capecitabine in the management of tumors of the digestive system.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms | 2009 |
Role of liver transplantation in the treatment of cholangiocarcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms | 2009 |
[Chemotherapy in gallbladder carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Capecitabine; Cisplatin; Deoxyc | 2010 |
[Thermo-chemo-radiotherapy for advanced biliary carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cisplatin; Combined Modality Th | 2006 |
[Adjuvant chemical treatment for bile duct cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Surgical Procedur | 2006 |
[Multimodal therapy for unresectable upper and hilar bile duct carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts; Brachytherapy; Cisp | 2006 |
Carcinoma-associated hemolytic-uremic syndrome in a patient receiving 5-fluorouracil-adriamycin-mitomycin C combination chemotherapy.
Topics: Adenocarcinoma; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasm | 1988 |
The prognosis and management of recurrent abdominal malignancies.
Topics: Abdominal Neoplasms; Adolescent; Adult; Antineoplastic Agents; Bile Duct Neoplasms; Chemotherapy, Ca | 1969 |
35 trials available for fluorouracil and Bile Duct Neoplasms
| Article | Year |
|---|---|
Treatment With Liposomal Irinotecan Plus Fluorouracil and Leucovorin for Patients With Previously Treated Metastatic Biliary Tract Cancer: The Phase 2b NIFTY Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cisplatin; Deoxycytidine; Femal | 2023 |
Hypofractionated Radiation Therapy for Unresectable/Locally Recurrent Intrahepatic Cholangiocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Bile Duct Neoplasms; Cholangiocarcinoma; Combined Modality Therapy; | 2020 |
Endoscopic radiofrequency ablation plus a novel oral 5-fluorouracil compound versus radiofrequency ablation alone for unresectable extrahepatic cholangiocarcinoma.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Extrah | 2020 |
First-line Treatment of Advanced Biliary Ducts Carcinoma: A Randomized Phase II Study Evaluating 5-FU/LV Plus Oxaliplatin (Folfox 4)
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Disease-Free Survival; Fe | 2017 |
Effects of ω-3 Fatty Acid Supplementation in Patients with Bile Duct or Pancreatic Cancer Undergoing Chemotherapy.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplas | 2018 |
Modified FOLFIRINOX versus CisGem first-line chemotherapy for locally advanced non resectable or metastatic biliary tract cancer (AMEBICA)-PRODIGE 38: Study protocol for a randomized controlled multicenter phase II/III study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinom | 2019 |
Interventionally implanted port catheter systems for hepatic arterial infusion of chemotherapy in patients with primary liver cancer: a phase II-study (NCT00356161).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrah | 2013 |
SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; | 2015 |
SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; | 2015 |
SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; | 2015 |
SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; | 2015 |
[Gemcitabine combined with capecitabine in the treatment for 41 patients with relapsed or metastatic biliary tract carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrah | 2008 |
[Assessment of the value of PEF (cisplatin, epirubicin, 5 fluorouracil) in advanced extrahepatic biliary tract and pancreatic cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrah | 2008 |
Phase II trial of gemcitabine combined with 5-fluorouracil and cisplatin (GFP) chemotherapy in patients with advanced biliary tree cancers.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2010 |
Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Deoxy | 2009 |
[Effects of pharmacokinetic modulation chemotherapy (PMC) using oral UFT and venous 5-FU infusion as adjuvant chemotherapy for intrahepatic cholangiocellular carcinoma].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pr | 2009 |
Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Ne | 2010 |
A Phase I-II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrah | 2011 |
A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; | 2011 |
Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Chemotherapy, Adju | 2002 |
Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplas | 2003 |
Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bi | 2004 |
Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcome.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineoplasti | 2004 |
Thermo-chemo-radiotherapy for advanced bile duct carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neo | 2005 |
A phase II study of LFP therapy (5-FU (5-fluorourasil) continuous infusion (CVI) and Low-dose consecutive (Cisplatin) CDDP) in advanced biliary tract carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma; Cisplatin; Dos | 2006 |
Radiochemotherapy followed by gemcitabine and capecitabine in extrahepatic bile duct cancer: a phase I/II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bi | 2006 |
Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2007 |
A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct N | 2007 |
Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Clinical Trials as Topic; Femal | 1984 |
[Clinical evaluation of combination chemotherapy of aclacinomycin A (ACM) and 5-fluorouracil (5-FU) for advanced carcinoma of gastrointestinal tract].
Topics: Aclarubicin; Antibiotics, Antineoplastic; Bile Duct Neoplasms; Clinical Trials as Topic; Colonic Neo | 1982 |
Protracted intravenous fluorouracil infusion with radiation therapy in the management of localized pancreaticobiliary carcinoma: a phase I Eastern Cooperative Oncology Group Trial.
Topics: Adult; Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Combined Modality Th | 1995 |
Epirubicin-sequential methotrexate-5-fluorouracil-leucovorin treatment in advanced cancer of the extrahepatic biliary system. A phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bi | 1994 |
A phase I study of combined radiation therapy with 5-fluorouracil and low dose folinic acid in patients with locally advanced pancreatic or biliary carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Com | 1996 |
Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neop | 1996 |
A phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Ca | 1998 |
Concomitant chemoradiation treatment in the management of patients with extrahepatic biliary tract recurrence of gastric carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrah | 2000 |
Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neopla | 2001 |
[Oxytetracycline, vehicle for therapeutic drugs, fluorouracil and nitrogen mustard, in the treatment of gastrointestinal tumors].
Topics: Adenocarcinoma; Adult; Bile Duct Neoplasms; Clinical Trials as Topic; Drug Combinations; Esophagus; | 1970 |
167 other studies available for fluorouracil and Bile Duct Neoplasms
| Article | Year |
|---|---|
Benzoyltyramine Alkaloids Atalantums A-G from the Peels of Atalantia monophylla and Their Cytotoxicity against Cholangiocarcinoma Cell Lines.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholang | 2017 |
FOXM1 inhibitor, Siomycin A, synergizes and restores 5-FU cytotoxicity in human cholangiocarcinoma cell lines via targeting thymidylate synthase.
Topics: Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cell Proliferation; Cell | 2021 |
Suppression of Cholangiocarcinoma Cell Growth and Proliferation by Atractylodes lancea (Thunb) DC. through ERK-Signaling Cascade.
Topics: Antineoplastic Agents; Atractylodes; Bile Duct Neoplasms; Cell Growth Processes; Cell Line, Tumor; C | 2021 |
Potential efficacy of hepatic arterial infusion chemotherapy using gemcitabine, cisplatin, and 5-fluorouracil for intrahepatic cholangiocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chola | 2022 |
Mesenchymal stem cell‑derived exosomes loaded with 5‑Fu against cholangiocarcinoma
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Exosomes; Fluorouracil; Humans; M | 2022 |
Apoptotic and Anti-metastatic Effects of Atractylodes lancea (Thunb.) DC. in a Hamster Model of Cholangiocarcinoma.
Topics: Animals; Atractylodes; bcl-2-Associated X Protein; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Ca | 2022 |
The Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Based on FOLFIRI for Advanced Intrahepatic Cholangiocarcinoma as Second-Line and Successive Treatment: A Real-World Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carci | 2022 |
Real-world outcomes among patients with advanced or metastatic biliary tract cancers initiating second-line treatment.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic | 2023 |
Use, response and outcomes of second-line chemotherapy in patients with advanced biliary tract cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neoplasms; Capeci | 2023 |
[Two Cases of Elderly Patients with Giant Intrahepatic Cholangiocarcinoma Treated with Multidisciplinary Therapy including Ablation Therapy].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile D | 2022 |
LncRNA FALEC increases the proliferation, migration and drug resistance of cholangiocarcinoma through competitive regulation of miR-20a-5p/SHOC2 axis.
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cell Movement; Cell Proliferation; | 2023 |
Increase of MAL-II Binding Alpha2,3-Sialylated Glycan Is Associated with 5-FU Resistance and Short Survival of Cholangiocarcinoma Patients.
Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Cell Line, Tumor; Cell Proliferation; Cholangi | 2019 |
Prolonged response to liposomal irinotecan in a patient with stage IV pancreatic/bile duct cancer previously treated with FOLFIRINOX and gemcitabine plus nab-paclitaxel.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Deoxycytidine; Fluoro | 2020 |
Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Capecitabine; Female; Flu | 2020 |
Is it Possible to Increase Survival of Patients with Intrahepatic Cholangiocarcinoma? A Case Report.
Topics: Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chemoradiotherapy, Adjuvant; Cholangiocarcinoma | 2021 |
Patterns of Failure and the Need for Biliary Intervention in Resected Biliary Tract Cancers After Chemoradiation.
Topics: Bile Duct Neoplasms; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Fluorouracil; Humans; Retrospe | 2020 |
Inhibition of Tumor Growth against Chemoresistant Cholangiocarcinoma by a Proapoptotic Peptide Targeting Interleukin-4 Receptor.
Topics: Animals; Apoptosis; Bile Duct Neoplasms; Carcinogenesis; Cell Line, Tumor; Cholangiocarcinoma; Drug | 2020 |
The importance of the "endoscopic oncologist" in the treatment of nonoperable cholangiocarcinoma.
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Fluorouracil; Humans; Oncologists | 2020 |
The ATO/miRNA-885-5p/MTPN axis induces reversal of drug-resistance in cholangiocarcinoma.
Topics: Antineoplastic Agents; Arsenic Trioxide; Bile Duct Neoplasms; Cell Line; Cell Line, Tumor; Cell Surv | 2021 |
Anticancer effects of the combined Thai noni juice ethanolic extracts and 5-fluorouracil against cholangiocarcinoma cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bile Duct Neoplasms; Cell Line, Tumor; Cholangiocarcinom | 2021 |
In Vitro Evaluation of Rigosertib Antitumoral and Radiosensitizing Effects against Human Cholangiocarcinoma Cells.
Topics: Antineoplastic Agents; Autophagy; Bile Duct Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Movement; | 2021 |
Adjuvant concurrent chemoradiotherapy with low-dose daily cisplatin for extrahepatic bile duct cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts | 2017 |
Effect of Adjuvant Gemcitabine Combined with Low-dose 5-Fluorouracil and Cisplatin Chemotherapy for Advanced Biliary Carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Chemotherapy, Adjuvant; C | 2017 |
Bevacizumab Added to Moderate-dose Chemotherapy for Refractory Uterine Cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols | 2018 |
Synergistic Effect of Forbesione From Garcinia hanburyi in Combination with 5-Fluorouracil on Cholangiocarcinoma
Topics: Animals; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Cholangiocarcinoma; Cricetinae; Drug | 2017 |
High expression of MMP-9 is associated with better prognosis in extrahepatic bile duct cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Extra | 2018 |
Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; | 2018 |
Effect of β-Eudesmol on NQO1 suppression-enhanced sensitivity of cholangiocarcinoma cells to chemotherapeutic agents.
Topics: Antineoplastic Agents; Apoptosis; Bile Duct Neoplasms; Cell Line, Tumor; Cell Movement; Cholangiocar | 2018 |
FOXM1 modulates 5-fluorouracil sensitivity in cholangiocarcinoma through thymidylate synthase (TYMS): implications of FOXM1-TYMS axis uncoupling in 5-FU resistance.
Topics: Apoptosis; Bile Duct Neoplasms; Cell Line, Tumor; Cell Survival; Cholangiocarcinoma; Drug Resistance | 2018 |
A 12-year Recurrence-free Survival After Multidisciplinary Treatment for a Patient With Combined Hepatocellular-Cholangiocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma, Hepatocellular; Chol | 2019 |
lnc-PKD2-2-3, identified by long non-coding RNA expression profiling, is associated with pejorative tumor features and poor prognosis, enhances cancer stemness and may serve as cancer stem-cell marker in cholangiocarcinoma.
Topics: Bile Duct Neoplasms; Biomarkers, Tumor; Cell Line, Tumor; Cholangiocarcinoma; Drug Resistance, Neopl | 2019 |
Radiotherapy or Chemoradiation in Unresectable Biliary Cancer: A Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Brachytherapy; | 2019 |
Prolonged Response to Anti-PD-1 Antibody Therapy in Chemotherapy-Refractory Cholangiocarcinoma With High Tumor Mutational Burden.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bile Duc | 2019 |
Raddeanin A promotes apoptosis and ameliorates 5-fluorouracil resistance in cholangiocarcinoma cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Bile Duct Neoplasms; Cell Line, Tumor; Cell Movement; | 2019 |
Evaluation of efficacy, safety and tolerability of high dose-intermittent calcitriol supplementation to advanced intrahepatic cholangiocarcinoma patients--a pilot study.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepat | 2012 |
CD24 expression predicts distant metastasis in extrahepatic bile duct cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Ex | 2013 |
A novel armed oncolytic measles vaccine virus for the treatment of cholangiocarcinoma.
Topics: Animals; Bile Duct Neoplasms; Cell Line, Tumor; Cholangiocarcinoma; Fluorouracil; Genetic Therapy; H | 2013 |
Neoadjuvant chemoradiotherapy followed by liver transplantation for unresectable cholangiocarcinoma: a single-centre national experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Brachyt | 2014 |
NK4 regulates 5-fluorouracil sensitivity in cholangiocarcinoma cells by modulating the intrinsic apoptosis pathway.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Caspase 3 | 2013 |
Retrospective analysis of survival benefits of chemotherapy for metastatic or non-resectable intrahepatic cholangiocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; | 2013 |
Adjuvant chemotherapy in resectable cholangiocarcinoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; | 2013 |
Treatment outcome of palliative chemotherapy in inoperable cholangiocarcinoma in Thailand.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; | 2013 |
Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for advanced-stage unresectable intrahepatic cholangiocarcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrah | 2013 |
Suppression of NAD(P)H-quinone oxidoreductase 1 enhanced the susceptibility of cholangiocarcinoma cells to chemotherapeutic agents.
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Bile Duct Neoplasms; Cell Line, Tumor; Cell Pr | 2014 |
Science to practice: Can we turn the undesired heating effects of MR imaging into effective cancer therapies?
Topics: Animals; Bile Duct Neoplasms; Cholangiocarcinoma; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; | 2014 |
Intrabiliary RF heat-enhanced local chemotherapy of a cholangiocarcinoma cell line: monitoring with dual-modality imaging--preclinical study.
Topics: Animals; Bile Duct Neoplasms; Cell Line, Tumor; Cholangiocarcinoma; Chromatography, High Pressure Li | 2014 |
Establishment and biological characterization of a novel cell line derived from hepatoid adenocarcinoma originated at the ampulla of Vater.
Topics: Adenocarcinoma; Aged; alpha-Fetoproteins; Ampulla of Vater; Animals; Antimetabolites, Antineoplastic | 2014 |
Notch1 is overexpressed in human intrahepatic cholangiocarcinoma and is associated with its proliferation, invasiveness and sensitivity to 5-fluorouracil in vitro.
Topics: Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Movement; Cell Proliferation; Cholangiocar | 2014 |
Efficacy of hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic pegylated interferon α-2b for advanced intrahepatic cholangiocarcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antivi | 2014 |
Long-term outcome of photodynamic therapy with systemic chemotherapy compared to photodynamic therapy alone in patients with advanced hilar cholangiocarcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrah | 2014 |
Outcome of Transplant-fallout Patients With Unresectable Cholangiocarcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Brachytherapy; Capecitabine; Chem | 2016 |
Gemcitabine, capecitabine and oxaliplatin in advanced biliary tract carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Capecitabine; Deoxycytidine; Dr | 2014 |
Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Duct | 2014 |
Immunogenic modulation of cholangiocarcinoma cells by chemoimmunotherapy.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Bile Duct Neoplas | 2014 |
Chemoradiotherapy for extrahepatic bile duct cancer with gross residual disease after surgery.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Chemora | 2014 |
Poor outcomes after liver transplantation in patients with incidental cholangiocarcinoma irrespective of tumor localization.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic | 2014 |
β-escin reverses multidrug resistance through inhibition of the GSK3β/β-catenin pathway in cholangiocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; beta | 2015 |
Repression of Nrf2 enhances antitumor effect of 5-fluorouracil and gemcitabine on cholangiocarcinoma cells.
Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Cell Line, Tumor; Cell Survival; Cholangiocarc | 2015 |
FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2015 |
Intraarterial 5-fluorouracil and interferon therapy is safe and effective for nonresectable biliary tract adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; | 2015 |
Establishment and characterization of gemcitabine-resistant human cholangiocarcinoma cell lines with multidrug resistance and enhanced invasiveness.
Topics: Bile Duct Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cholangiocarcinoma; Deoxycytidi | 2015 |
Targeting the ∆133p53 isoform can restore chemosensitivity in 5-fluorouracil-resistant cholangiocarcinoma cells.
Topics: Aged; Antineoplastic Agents; Apoptosis; Bile Duct Neoplasms; Blotting, Western; Cell Line, Tumor; Ce | 2015 |
TRAIL in Combination with Subtoxic 5-FU Effectively Inhibit Cell Proliferation and Induce Apoptosis in Cholangiocarcinoma Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bile Duct Neoplasms; Caspases; Cell Line, | 2015 |
Sensitivity of Human Intrahepatic Cholangiocarcinoma Subtypes to Chemotherapeutics and Molecular Targeted Agents: A Study on Primary Cell Cultures.
Topics: Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Anilides; Animals; Antineoplastic Combined Chemot | 2015 |
Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; | 2016 |
Inhibition of NF-κB Activity Enhances Sensitivity to Anticancer Drugs in Cholangiocarcinoma Cells.
Topics: Antineoplastic Agents; Apoptosis; ATP-Binding Cassette Transporters; Benzamides; Bile Duct Neoplasms | 2016 |
Photodynamic Therapy Plus Chemotherapy Compared with Photodynamic Therapy Alone in Hilar Nonresectable Cholangiocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cholangiocarcinoma; Cispl | 2016 |
Regional thermochemotherapy versus hepatic arterial infusion chemotherapy for palliative treatment of advanced hilar cholangiocarcinoma: a retrospective controlled study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cisplatin; Combine | 2016 |
Irinotecan Plus Gemcitabine and Fluorouracil in Advanced Biliary Tract Cancer: A Retrospective Study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Ca | 2016 |
Upregulation of retinoic acid receptor-β reverses drug resistance in cholangiocarcinoma cells by enhancing susceptibility to apoptosis.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Bile Duct Neoplasms; Bile Ducts; Cell Line, Tum | 2016 |
[Efficacy of Combined Therapy(Drainage of the Bile Duct, High-Dose Hepatic Artery Infusion, and Radiation)for Hilar Cholangiocellularcarcinoma with Complete Portal Vein Obstruction].
Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Chemoradiotherapy; Cholangiocarcinoma; D | 2016 |
Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Cholangiocarcinom | 2009 |
Epigallocatechin-gallate modulates chemotherapy-induced apoptosis in human cholangiocarcinoma cells.
Topics: Animals; Anticarcinogenic Agents; Apoptosis; Bile Duct Neoplasms; Blotting, Western; Camellia sinens | 2009 |
Oncolytic gene therapy combined with double suicide genes for human bile duct cancer in nude mouse models.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Antiviral Agents; Bile Duct Neoplasms; Bile | 2009 |
Thymidylate synthase and dihydropyrimidine dehydrogenase are upregulated in pancreatic and biliary tract cancers.
Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Biliary Tract Neoplasms; Dihydrouracil Dehydro | 2009 |
[A case of successful multimodal treatment for combined hepatocellular and cholangiocarcinoma with portal venous tumor thrombus].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2009 |
Combination of bilateral metal stenting and trans-stent photodynamic therapy for palliative treatment of hilar cholangiocarcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile D | 2010 |
Time to move to targeted drugs in biliary tract cancer?
Topics: Adenocarcinoma; Ampulla of Vater; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineo | 2010 |
Preliminary experience of cetuximab in the treatment of advanced-stage biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
Effects of thymidine phosphorylase on tumor aggressiveness and 5-fluorouracil sensitivity in cholangiocarcinoma.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Bile Duct Neoplasms; Carcinoma, Squamous Cell; Cell Line | 2010 |
Long-term culture following ES-like gene-induced reprogramming elicits an aggressive phenotype in mutated cholangiocellular carcinoma cells.
Topics: Animals; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Cultur | 2010 |
Fatal immune haemolysis due to antibodies to individual metabolites of 5-fluorouracil.
Topics: Anemia; Anemia, Hemolytic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pro | 2010 |
Postoperative chemoradiotherapy for extrahepatic bile duct cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; CA-19-9 | 2011 |
Adjuvant chemoradiotherapy after curative resection for extrahepatic bile duct cancer: a long-term single center experience.
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; B | 2012 |
Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell | 2011 |
COP35, a cholangiocarcinoma-binding oligopeptide, interacts with the clathrin heavy chain accompanied by GRP78.
Topics: Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cholangiocar | 2011 |
Neoadjuvant therapy protocol and liver transplantation in combination with pancreatoduodenectomy for the treatment of hilar cholangiocarcinoma occurring in a case of primary sclerosing cholangitis: case report with a more than 8-year disease-free survival
Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Brachytherapy; Chemo | 2011 |
Adjuvant radio-chemotherapy for extrahepatic biliary tract cancers.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; | 2011 |
[Effectiveness of systemic chemotherapy of GEM+CBDCA+5-FU/LV and hepatic arterial infusion of CDDP in a case of advanced, combined hepatocellular-cholangiocarcinoma with multiple lung metastases].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2011 |
Acute inflammatory demyelinating polyradiculoneuropathy in a patient receiving oxaliplatin-based chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cholangiocarcinoma; Fluorouraci | 2012 |
Chemotherapy for inoperable advanced or metastatic cholangiocarcinoma: retrospective analysis of 78 cases in a single center over four years.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrah | 2012 |
Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bile Duct Neoplasms; Bi | 2012 |
Synergic effect of photodynamic therapy using talaporfin sodium with conventional anticancer chemotherapy for the treatment of bile duct carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bile Duct | 2013 |
Orotate phosphoribosyl transferase mRNA expression and the response of cholangiocarcinoma to 5-fluorouracil.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Su | 2012 |
Fluoropyrimidines plus cisplatin versus gemcitabine/gemcitabine plus cisplatin in locally advanced and metastatic biliary tract carcinoma - a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; | 2012 |
Novel multimodality treatment sequencing for extrahepatic (mid and distal) cholangiocarcinoma.
Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Brachytherapy; Chola | 2013 |
Adjuvant therapy for intrahepatic cholangiocarcinoma: the debate continues.
Topics: Adenocarcinoma; Adult; alpha-Fetoproteins; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biomarkers | 2012 |
[Combination therapy for inoperable cholangiocellular carcinoma-systemic chemotherapy and hepatic arterial injection].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chola | 2012 |
[Two long-term survival cases of unresectable intrahepatic cholangiocarcinoma treated with hepatic arterial infusion chemotherapy and radiation therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; | 2012 |
Challenge in differential diagnosis of a liver mass histologically defined as a metastatic lesion from an occult primary intestinal tumour. The importance of clinical findings and the limitations of histology and molecular profiles. A case report.
Topics: Adenoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intr | 2012 |
Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma.
Topics: Adult; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarc | 2002 |
Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma.
Topics: Adult; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarc | 2002 |
Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma.
Topics: Adult; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarc | 2002 |
Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma.
Topics: Adult; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarc | 2002 |
Combined external beam and intraluminal radiotherapy for irresectable Klatskin tumors.
Topics: Aged; Aged, 80 and over; Bile Duct Neoplasms; Brachytherapy; Chemotherapy, Adjuvant; Combined Modali | 2002 |
CHEMOTHERAPY OF METASTATIC LIVER CANCER BY PROLONGED HEPATIC-ARTERY INFUSION.
Topics: Alkaline Phosphatase; Bile Duct Neoplasms; Bilirubin; Chemotherapy, Cancer, Regional Perfusion; Colo | 1964 |
5-FLUOROURACIL (NSC-19893) TREATMENT OF ADVANCED CANCER IN AMBULATORY PATIENTS.
Topics: Ampulla of Vater; Bile Duct Neoplasms; Breast Neoplasms; Colonic Neoplasms; Fluorouracil; Humans; Ne | 1963 |
Radiotherapy combined with transarterial infusion chemotherapy and concurrent infusion of a vasoconstrictor agent for nonresectable advanced hepatic hilar duct carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile D | 2004 |
Treatment of advanced digestive non-colon cancer with a weekly 24-h infusion of high-dose 5-fluorouracil modulated by folinic acid and cisplatin: an easy-to-use and well-tolerated combination.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Ci | 2004 |
Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.
Topics: Administration, Oral; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Carcinoma, Hepato | 2004 |
Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.
Topics: Administration, Oral; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Carcinoma, Hepato | 2004 |
Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.
Topics: Administration, Oral; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Carcinoma, Hepato | 2004 |
Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.
Topics: Administration, Oral; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Carcinoma, Hepato | 2004 |
Cholangiocarcinoma: advocate an aggressive operative approach with adjuvant chemotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chemotherapy, | 2004 |
[Successful treatment for advanced cholangiocellular carcinoma with intrahepatic metastasis and/or portal vein tumor thrombi by intraarterial chemotherapy combined with 5-fluorouracil, adriamycin and cisplatin (FAP)--two cases report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; | 2004 |
[Adjuvant arterial infusion chemotherapy for patients with biliary cancer].
Topics: Adult; Aged; Aged, 80 and over; Ampulla of Vater; Bile Duct Neoplasms; Biliary Tract Neoplasms; Chem | 2004 |
Chemoradiation may prolong survival of patients with non-bulky unresectable extrahepatic biliary carcinoma. A retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; | 2004 |
Chemoradiation and brachytherapy in biliary tract carcinoma: long-term results.
Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, | 2006 |
[Low-dose cisplatin plus 5-fluorouracil with radiotherapy for unresectable upper and hilar bile duct carcinoma].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms | 2005 |
[The evaluation of chemoradiotherapy to unresectable hepatobiliary cancers].
Topics: Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Combined Modalit | 2005 |
[A case of unresectable cholangiocellular carcinoma treated with surgery followed by combination chemotherapy].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2005 |
[A case of postoperative liver metastasis from bile duct carcinoma responding to transarterial chemoembolization].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Chemoembo | 2006 |
Tannic acid synergizes the cytotoxicity of chemotherapeutic drugs in human cholangiocarcinoma by modulating drug efflux pathways.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfami | 2007 |
[A case of intrahepatic cholangiocarcinoma effectively treated by hepatic arterial infusion chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Bone | 2006 |
[A 42-month disease free survival case of combined hepatocellular-cholangiocarcinoma with lymph node metastases treated with multimodal therapy].
Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, | 2006 |
Effects of the anti-epidermal growth factor receptor antibody cetuximab on cholangiocarcinoma of the liver.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2007 |
Unexpected response to systemic chemotherapy in case of primarily nonresectable advanced disseminated intrahepatic cholangiocarcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic | 2007 |
Effects of targeting magnetic drug nanoparticles on human cholangiocarcinoma xenografts in nude mice.
Topics: Animals; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Fluorouracil; Humans; Ma | 2007 |
[A long-term survival case of unresectable hepatohilar bile duct cancer treated with radiotherapy and hepatic arterial infusion chemotherapy ].
Topics: Aged; Bile Duct Neoplasms; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Liver Neoplasms; | 2007 |
Hepatic artery infusion of 5-fluorouracil and mitomycin C in cholangiocarcinoma and gallbladder carcinoma.
Topics: Adenoma, Bile Duct; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms | 1984 |
Long survival following combined treatment of inoperable cholangiocarcinoma: surgery, radiotherapy, and chemotherapy.
Topics: Adenoma, Bile Duct; Bile Duct Neoplasms; Cobalt Radioisotopes; Cyclophosphamide; Drainage; Fluoroura | 1980 |
Management of high bile duct carcinoma.
Topics: Adenocarcinoma; Adenoma, Bile Duct; Aged; Bile Duct Neoplasms; Bile Ducts; Combined Modality Therapy | 1984 |
Analysis of failure following curative irradiation of gallbladder and extrahepatic bile duct carcinoma.
Topics: Adult; Aged; Bile Duct Neoplasms; Brachytherapy; Combined Modality Therapy; Electrons; Female; Fluor | 1984 |
[Palliative therapy of primary liver tumors].
Topics: Adenoma, Bile Duct; Adolescent; Adult; Aged; alpha-Fetoproteins; Angiography; Antineoplastic Combine | 1993 |
[A case of liver metastasis from bile duct cancer effectively treated with hepatic artery infusion chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Drug Administration Schedule; E | 1994 |
[A case of successful management of advanced cholangiocellular carcinoma by repeated hepatic resection].
Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Hepatocel | 1996 |
[Trial of home anti-cancer chemotherapy with infusion of 5-FU and low-dose cisplatin].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cisplatin; Colonic Neopla | 1996 |
Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepati | 1997 |
Long-term survival of a young woman with peripheral cholangiocarcinoma: a case report.
Topics: Adult; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chemotherapy, | 1999 |
[A case report: successful resection of advanced intrahepatic cholangiocarcinoma responding to preoperative hepatic artery infusion of 5-FU].
Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; | 1999 |
[A case of successful management of nonresectable advanced cholangiocellular carcinoma by intermittent hepatic arterial infusion at home].
Topics: Aged; Aged, 80 and over; Ambulatory Care; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Carc | 2000 |
[Lymph node and peritoneum metastases of bile duct cancer responding to chronochemotherapy--a case report].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cisplatin | 2000 |
Arterial chemoinfusion therapy through an implanted port system for patients with unresectable intrahepatic cholangiocarcinoma--initial experience.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2002 |
Prognostic factors after pancreatoduodenectomy with extended lymphadenectomy for distal bile duct cancer.
Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Chemotherapy, Adjuvant; Cholangiocarcinoma; Fe | 2002 |
[Conformal therapy of locally advanced cholangiocarcinoma of the main bile ducts].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2002 |
Capecitabine as second-line treatment for metastatic cholangiocarcinoma: a report of two cases.
Topics: Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Cholangiocarcinoma; Deoxycytidine | 2002 |
Limitations of conventional doses of chemoradiation for unresectable biliary cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, In | 2002 |
Carcinoma of the periampullary region: a review of a personal series of 87 patients.
Topics: Adult; Aged; Ampulla of Vater; Bile Duct Neoplasms; Drainage; Duodenum; Female; Fluorouracil; Humans | 1976 |
Management of carcinoma of the extrahepatic bile ducts.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Bile Duct Neoplasms; Carcinoma, Squamous Cell; Child; Commo | 1978 |
[Chemotherapy for digestive carcinomas. Results of a phase II clinical trial (author's transl)].
Topics: Bile Duct Neoplasms; Colonic Neoplasms; Drug Evaluation; Drug Therapy, Combination; Esophageal Neopl | 1979 |
Chemotherapy of metastatic gastrointestinal neoplasms with 5-fluorouracil and streptozotocin.
Topics: Adenocarcinoma; Adenoma, Bile Duct; Adenoma, Islet Cell; Adult; Aged; Bile Duct Neoplasms; Carcinoid | 1977 |
Adenocarcinoma of the bile ducts. Relationship of anatomic location to clinical features.
Topics: Adenocarcinoma; Adult; Aged; Alkaline Phosphatase; Bile Duct Neoplasms; Bile Ducts; Bile Ducts, Intr | 1975 |
[Digestive tract cancer: planning of chemotherapy].
Topics: Bile Duct Neoplasms; Cytarabine; Drug Therapy, Combination; Fluorouracil; Gallbladder Neoplasms; Hum | 1975 |
Immunostimulation with intraperitoneally administered bacille Calmette Guérin for advanced malignant tumors of the gastrointestinal tract.
Topics: Adult; Aged; BCG Vaccine; Bile Duct Neoplasms; Carcinoma; Colonic Neoplasms; Cyclophosphamide; Femal | 1976 |
Analysis of failure after curative irradiation of extrahepatic bile duct carcinoma.
Topics: Adenoma, Bile Duct; Adult; Aged; Aged, 80 and over; Bile Duct Neoplasms; Combined Modality Therapy; | 1992 |
[Cases of advanced cholangiocarcinoma showing partial response by the combination chemotherapy including protracted continuous infusion of 5-FU combined with intravenous administration of low-dose leucovorin and intra-arterial administration of MMC and CQ
Topics: Adenoma, Bile Duct; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carbazilqui | 1991 |
[Neoplasms of the gallbladder and the extrahepatic bile ducts: radio-chemotherapeutic combined treatment. Results in 18 treated cases].
Topics: Adult; Aged; Bile Duct Neoplasms; Clinical Protocols; Combined Modality Therapy; Female; Fluorouraci | 1991 |
[Intraarterial and intraportal chemotherapy combined with decollateralization for cholangiocellular carcinoma and metastatic liver cancer].
Topics: Adenoma, Bile Duct; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile | 1990 |
Adjuvant radiochemotherapy following orthotopic liver transplantation for bile duct cancer.
Topics: Adult; Bile Duct Neoplasms; Combined Modality Therapy; Doxorubicin; Female; Fluorouracil; Humans; Li | 1990 |
[Intraductal chemotherapy of bile duct cancer with 5-fluorouracil].
Topics: Adenocarcinoma; Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chemotherapy, Cancer, Regional | 1986 |
[Intra-arterial and intraportal therapy combined with decollateralization in unresectable cholangiocellular carcinoma--a case report].
Topics: Adenoma, Bile Duct; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, | 1989 |
[Combined hepatic arterial infusion chemotherapy with transcatheter arterial embolization and hyperthermia in primary liver cancer].
Topics: Adenoma, Bile Duct; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma, | 1988 |
[A case of abdominal wall fistula due to cholangioma].
Topics: Abdominal Muscles; Adenoma, Bile Duct; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neo | 1985 |
[A case of intrahepatic bile duct cancer responding to 5-fluorouracil, adriamycin and mitomycin C chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Int | 1988 |
[MQF-FT and MQF-UFT in gallbladder and bile duct cancer].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Car | 1988 |
125I interstitial implant, precision high-dose external beam therapy, and 5-FU for unresectable adenocarcinoma of pancreas and extrahepatic biliary tree.
Topics: Adenocarcinoma; Aged; Bile Duct Neoplasms; Brachytherapy; Female; Fluorouracil; Humans; Male; Middle | 1986 |
Hepatic artery infusion for metastatic malignancy using percutaneously placed catheters.
Topics: Adenoma, Islet Cell; Adult; Aged; Bile Duct Neoplasms; Breast Neoplasms; Carcinoid Tumor; Carcinoma, | 1971 |
[Selection of a method for treating cancer of the pancreaticoduodenal region].
Topics: Bile Duct Neoplasms; Cyclophosphamide; Duodenal Neoplasms; Fluorouracil; Gallbladder Neoplasms; Huma | 1971 |
Adenocarcinomas of stomach, pancreas, liver, and biliary tracts. Survival of 328 patients treated with fluoropyrimidine therapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Bile Duct Neoplasms; Evaluation Studies as Topic; Floxuridine | 1974 |
Experience with hepatic arterial infusions.
Topics: Adult; Aged; Bile Duct Neoplasms; Carcinoma, Hepatocellular; Female; Floxuridine; Fluorouracil; Gall | 1971 |
Carcinoma of the common bile duct. Report of an unusual two-year remission after intraluminal 5-fluorouracil.
Topics: Adenocarcinoma, Papillary; Bile Duct Neoplasms; Cholangiography; Common Bile Duct; Female; Fluoroura | 1972 |
[Intra-arterial infusion of drugs into the liver and pancreas].
Topics: Bile Duct Neoplasms; Cyclophosphamide; Duodenal Neoplasms; Fluorouracil; Humans; Injections, Intra-A | 1971 |
Oral administration of fluorouracil. A preliminary trial.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Bile Duct Neoplasms; Colonic Neoplasms; Diarrhea; Fluorouraci | 1968 |